JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

Selectivity Barriers in the Therapeutic Target Validation of β-Secretase-1 in the Pathogenesis of Alzheimer's Disease

Muazu Usman Muhammad*[1], Parameswar G V[1], Hindat Mustapha Ladan[2], Aslam Muazu Muhammad[3], Hauwa'u Abdulaziz Lawal[4]

[1] *Department of Pharmacology, Raghavendra Institute of Pharmaceutical Education and Research, Anantapur, Andhra Pradesh, India*
[2] *Department of Anatomy, Yusuf Maitama Sule University, Kano, Nigeria*
[3] *Department of Biology, Federal University Dutse, Jigawa, Nigeria*
[4] *Department of Pharmacy, Usmanu Danfodiyo University, Sokoto, Nigeria*

Publication history: Received on 28th March 2026; Revised on 3rd May 2026; Accepted on 4th May 2026

Article DOI: 10.69613/jvyw7v28

Abstract: Inhibition of β-site amyloid precursor protein cleaving enzyme 1 (BACE1) is a primary therapeutic mechanism aimed at reducing amyloid-β (Aβ) plaque deposition in Alzheimer's disease. Despite achieving pronounced reduction of cerebrospinal fluid Aβ in clinical trials, numerous small-molecule BACE1 inhibitors, including verubecestat, lanabecestat, and umibecestat, were discontinued due to a lack of clinical efficacy, paradoxical cognitive decline, and systemic adverse events. These setbacks highlight the critical challenge of therapeutic selectivity, which encompasses both off-target cross-reactivity with homologous aspartyl proteases and on-target disruption of non-amyloidogenic BACE1 physiological pathways. Homologous enzymes such as BACE2 and lysosomal Cathepsin D share high structural identity within their catalytic domains, and their inadvertent inhibition induces hair depigmentation and retinal toxicity, respectively. Simultaneously, absolute blockade of BACE1 impairs the processing of essential neuronal substrates, including neuregulin-1 and seizure protein 6, thereby compromising myelination and synaptic plasticity. Resolving these therapeutic barriers requires advanced drug design approaches, such as structure-based optimization targeting the unique conformation of the BACE1 active-site subsites, fragment-based discovery, and the development of non-competitive or allosteric modulators. In addition, implementing precision dosing regimens to achieve moderate enzyme inhibition rather than complete ablation, combined with early biomarker-guided intervention in pre-symptomatic patient cohorts, constitutes the most viable framework for the clinical translation of BACE1-targeted therapies.

Keywords: BACE1 inhibitors; Alzheimer's disease; BACE2; Cathepsin D; Selectivity; Drug discovery.

1. Introduction

Alzheimer's disease (AD) is a major public health challenge, characterized clinically by progressive dementia, memory loss, and cognitive decline [1]. The histopathological hallmarks of the disease are defined by the accumulation of extracellular senile plaques composed of amyloid-β (Aβ) peptides and intracellular neurofibrillary tangles containing hyperphosphorylated microtubule-associated tau proteins [2]. According to the amyloid cascade hypothesis, the accumulation, oligomerization, and deposition of Aβ in the cerebral cortex initiate a cascade of pathological events, including synaptic dysfunction, chronic neuroinflammation, oxidative stress, and progressive neuronal death [3]. Consequently, therapeutic strategies aimed at reducing Aβ generation have remained at the forefront of neurodegenerative drug discovery for several decades [4].

The generation of Aβ from the type I transmembrane glycoprotein amyloid precursor protein (APP) requires sequential proteolytic cleavages mediated by two distinct enzymatic complexes [5]. The initial, rate-limiting step is executed by β-secretase, also known as β-site APP cleaving enzyme 1 (BACE1), which cleaves APP at the N-terminus of the Aβ sequence (between Met671 and Asp672 of the APP 770 isoform) [6]. This endoproteolytic event releases a soluble ectodomain (sAPPβ) into the extracellular space and leaves a 99-amino-acid C-terminal fragment (C99 or β-CTF) anchored within the lipid bilayer [7]. The C99 fragment subsequently undergoes intramembrane proteolysis by the intramembrane multi-protein γ-secretase complex, which cleaves the fragment at variable positions to release pathogenic Aβ monomers (primarily Aβ 40 and the highly hydrophobic, aggregation-prone Aβ 42 species) into the extracellular parenchyma [8].

Because BACE1 initiates the amyloidogenic processing pathway, it has long been validated as an exceptional drug target [9]. Unlike γ-secretase, whose therapeutic targeting was severely hindered by the critical role of Notch-1 signaling in cellular differentiation,

* Corresponding author: Muazu Usman Muhammad

BACE1 genetic deletion in murine models appeared to yield viable offspring, further elevating its status as a highly tractable drug target [10]. This prompted extensive research efforts by global pharmaceutical entities to design, synthesize, and clinically evaluate small-molecule BACE1 inhibitors capable of crossing the blood-brain barrier (BBB) to halt Aβ production at its source [11].

Despite the discovery of several highly potent, brain-penetrant small molecules that showed robust, dose-dependent reductions in cerebrospinal fluid (CSF) and brain parenchyma Aβ concentrations during preclinical testing, the clinical development of BACE1 inhibitors has been marked by repeated, high-profile failures in Phase II and Phase III clinical trials [12]. Clinical candidates such as verubecestat (MK-8931), lanabecestat (AZD3293), atabecestat (JNJ-54861911), and umibecestat (CNP520) were systematically abandoned [13]. Crucially, these terminations were not triggered by a failure to target the enzyme, as many of these candidates achieved greater than 80% suppression of Aβ in human subjects [14]. Instead, the trials were halted due to futility, liver toxicity, and, most paradoxically, a dose-dependent worsening of cognitive performance in treated patients compared to the placebo group [15].

These clinical outcomes showed that potency alone is insufficient for successful therapeutic intervention, highlighting the complex challenge of enzyme selectivity [16]. The pathological liabilities of BACE1 inhibition are broadly categorized into two distinct mechanisms: off-target cross-reactivity with structurally related aspartyl proteases and on-target toxicity resulting from the excessive depletion of native physiological BACE1 substrates [17]. The active site of BACE1 shares structural homology with other human aspartic proteases, most notably its close phylogenetic relative BACE2 and the lysosomal protease Cathepsin D (CatD) [18]. Inadvertent inhibition of these off-target enzymes causes severe systemic toxicities, including ocular degeneration and cutaneous pigment changes [19]. BACE1 is now known to possess a diverse array of non-APP physiological substrates that are critical for axonal guidance, myelination, and synaptic plasticity [20]. Achieving BACE1 selectivity both structural selectivity against related proteases and functional selectivity to maintain basic physiological substrate processing remains the fundamental bottleneck in the ongoing refinement of BACE1-targeted therapeutics [21].

2. Biochemistry and Physiological Roles of BACE1 and Homologous Proteases

2.1. BACE1 Structural Architecture and Catalytic Mechanism

2.1.1. Structural Domains, Disulfide Bonds, and the Catalytic Dyad

BACE1 is synthesized as an inactive 501-amino-acid preproenzyme containing a 21-residue signal peptide and a 24-residue propeptide domain [22]. Following translation, the signal peptide directs the nascent polypeptide to the rough endoplasmic reticulum, where it is cleaved. The remaining proenzyme undergoes transport through the secretory pathway, during which the propeptide domain is removed by proprotein convertases (such as furin) in the trans-Golgi network (TGN) to yield the mature, catalytically active 456-amino-acid enzyme [23]. Mature BACE1 is structured as a type I transmembrane glycoprotein consisting of an extracellular catalytic domain (residues 1–454), a single hydrophobic transmembrane anchor (residues 455–477), and a short, highly conserved carboxyl-terminal cytosolic tail (residues 478–501) that regulates its subcellular trafficking and endosomal localization [24].



Figure 1. Catalytic Cleft of BACE1 and Structural Selectivity Anchors

The extracellular catalytic domain of BACE1 exhibits the classic bilobal fold characteristic of the pepsin-like family of aspartic proteases, comprising an amino-terminal lobe and a carboxy-terminal lobe [25]. The junction of these two structural lobes forms a deep, elongated cleft that houses the catalytic machinery. This active site is defined by two highly conserved aspartic acid motifs, Asp32 (located in the N-terminal lobe) and Asp228 (located in the C-terminal lobe) [26]. These catalytic residues operate as a coordinated dyad, projecting their carboxylate side chains into the center of the active cleft. The mechanism of peptide bond hydrolysis depends on the protonation states of these two residues: one aspartate exists in a deprotonated state to act as a general base, activating a highly coordinated, nucleophilic water molecule, while the second aspartate remains protonated to act as a general acid, protonating the nitrogen atom of the substrate's scissile peptide bond [27].

The structural integrity of this catalytic cleft is stabilized by three pairs of highly conserved, intramolecular disulfide bonds: Cys216–Cys420, Cys278–Cys443, and Cys330–Cys380 [28]. These covalent linkages restrict the conformational freedom of the enzyme, maintaining the precise spatial alignment of the catalytic dyad. Additionally, BACE1 possesses several unique sequence insertions and a hydrophilic surface area that render its active-site cleft larger, more open, and significantly more accessible to bulky macromolecular substrates than traditional, soluble aspartic proteases such as pepsin or renin [29].

2.1.2. Active Site Subsites and Flap Dynamics

The extended substrate-binding pocket of BACE1 is subdivided into distinct subsites (S1, S2, S3, S4 on the N-terminal side of the scissile bond, and S1', S2', S3' on the C-terminal side), which accommodate the corresponding amino acid side chains (P4 to P3') of the substrate peptide [30]. The spatial geometry and electrostatic properties of these subsites dictate the substrate specificity of the enzyme:

- The S1 subsite is a hydrophobic, pocket-like structure that shows a strong preference for large, hydrophobic amino acid residues such as leucine, phenylalanine, or methionine at the P 1 position of the substrate [31].
- The S2 subsite is relatively small and hydrophilic, preferring polar or basic residues.
- The S3 subsite is a large, hydrophobic cavity that exhibits significant structural plasticity and can accommodate bulky aromatic side chains.
- The S1' subsite is relatively hydrophobic and is situated adjacent to the catalytic dyad [32].

Crucial to the regulation of substrate entry and catalytic cycle progression is a highly flexible, structurally conserved β-hairpin loop known as the "flap" (spanning residues Val67 to Glu77, with the triad Val69–Tyr71 forming the apex) [33]. The flap acts as a molecular gatekeeper for the active site, dynamically oscillating between an "open" conformation, which permits substrate access to the catalytic cleft, and a "closed" conformation, which drapes over the active site to lock the substrate in close proximity to the catalytic dyad for cleavage [34]. Upon ligand binding, the flap undergoes a major conformational transition, shifting downward by up to 5 AA to establish hydrophobic contacts with the bound substrate, a mechanism that must be precisely accommodated during the design of synthetic inhibitors [35].

2.2. BACE1 Physiological Substrates and Phenotypic Knockout Profiles

2.2.1. Amyloid Precursor Protein Processing

The primary and most widely characterized substrate of BACE1 is the amyloid precursor protein (APP) [36]. BACE1 mediates the initial, rate-limiting step of the amyloidogenic pathway by cleaving APP at the designated β-site [37]. Under physiological conditions, however, APP undergoes non-amyloidogenic processing via a competitive pathway mediated by α-secretase (primarily metalloproteases such as ADAM10), which cleaves APP within the Aβ domain (between Lys687 and Leu688), thereby precluding the formation of the intact neurotoxic Aβ peptide [38]. The competition between α-secretase and BACE1 for the shared pool of membrane-bound APP is highly dependent on subcellular localization. While α-secretase operates predominantly at the neutral pH of the plasma membrane, BACE1 exhibits an acidic pH optimum (pH 3.5–5.5) [39]. Consequently, BACE1-mediated cleavage of APP occurs primarily within the acidic lumens of the trans-Golgi network, late endosomes, and lysosomes, where BACE1 is concentrated via clathrin-mediated endocytosis regulated by the phosphorylation of its cytosolic Ser498 residue [40].

2.2.2. Non-Amyloidogenic Substrates

Beyond its role in APP processing, quantitative proteomic analyses have identified dozens of non-amyloidogenic transmembrane proteins that serve as native substrates for BACE1, primarily within the central and peripheral nervous systems [41]. Among these, three substrates are of paramount physiological importance:

- Neuregulin-1 (NRG1): BACE1 cleaves the membrane-bound precursor of type I and type III NRG1 [42]. The liberated, biologically active NRG1 ectodomain binds to ErbB3/ErbB4 receptor tyrosine kinases on myelinating glia, triggering

intracellular cascades that regulate the myelination of peripheral axons by Schwann cells and central axons by oligodendrocytes.

- Seizure Protein 6 (Sez6): Sez6 is a transmembrane protein highly expressed in cortical neurons, where it is cleaved by BACE1 to release its soluble ectodomain [43]. This cleavage is essential for normal dendritic spine development, synaptic pruning, and excitatory synaptic transmission.
- Close Homolog of L1 (CHL1): CHL1 is a neural cell adhesion molecule involved in axonal growth, guidance, and fasciculation. Cleavage of CHL1 by BACE1 is required to regulate proper thalamocortical axon projection and the assembly of neuronal circuitry in the developing brain [44].



Figure 2. Amyloidogenic vs. Non-Amyloidogenic APP Processing

Additionally, BACE1 processes other neurophysiologically active molecules, such as the voltage-gated sodium channel auxiliary β 2 subunit (Navβ 2), which regulates the cell-surface density and conductance of mature sodium channels (Nav1.1 and Nav1.2), and the adhesion molecule contactin-2, which is involved in organizing the nodes of Ranvier [45].

2.2.3. Neurological Phenotypes of Genetic Deletion

The physiological significance of these alternative substrates is highlighted by the phenotypic abnormalities observed in genetic BACE1 knockout (BACE1$^{-/-}$) mice [46]. Although early studies suggested that BACE1-null mice were healthy and fertile, comprehensive phenotypic profiling has revealed a complex array of neurological deficits:

- Hypomyelination: Due to the failure of NRG1 processing, BACE1$^{-/-}$ mice exhibit significant hypomyelination of both peripheral and central axons, leading to decreased nerve conduction velocity and mild sensorimotor deficits [47].
- Seizure Susceptibility: Defective processing of Sez6 and the Navβ 2 subunit alters neuronal excitability and sodium channel dynamics, rendering BACE1$^{-/-}$ mice highly susceptible to spontaneous epileptiform seizures and pharmacological induction of convulsive activity [48].
- Axonal Guidance Defects: Aberrant accumulation of Uncleaved CHL1 in hippocampal and thalamic neurons results in profound axon targeting errors, particularly within the mossy fiber pathway of the hippocampus, which directly correlates with deficits in spatial learning and memory consolidation [49].
- Synaptic and Cognitive Deficits: BACE1$^{-/-}$ mice show impaired long-term potentiation (LTP) in the CA1 region of the hippocampus, accompanied by an overall reduction in dendritic spine density, leading to cognitive impairments that mimic aspects of the dementia they were designed to prevent [50].

These phenotypes show that absolute, long-term pharmacological blockade of BACE1 in human patients carries a substantial risk of recapitulating these developmental and synaptic pathologies, particularly regarding cognitive stability and axonal maintenance [51].

2.3. BACE2 Architecture and Physiological Roles

2.3.1. Phylogenetic and Sequence Homology with BACE1

BACE2 is a 518-amino-acid membrane-anchored aspartyl protease that represents the closest phylogenetic paralog of BACE1, with the two genes co-localizing on chromosome 21 in humans [52]. The mature forms of BACE1 and BACE2 exhibit approximately 64% sequence similarity and 45% strict sequence identity [53]. This extensive sequence conservation is even more pronounced within the active-site cleft, where the amino acid residues lining the S 1 and S2 subsites are nearly identical between the two enzymes [54]. Evolutionary trace methodologies and X-ray crystallographic comparisons reveal that the spatial organization of the catalytic machinery including the Asp32/Asp228 dyad and the flexible β-hairpin flap is highly conserved in BACE2 [55]. However, their expression profiles differ significantly: while BACE1 is highly expressed in neurons within the central nervous system, BACE2 expression is comparatively low in the brain, localized instead in peripheral tissues, including the skin, pancreas, kidneys, and breast tissue [56].

2.3.2. Cleavage of PMEL17 and Pigmentary Phenotypes

Functionally, BACE2 does not act as an amyloidogenic enzyme; rather, it cleaves APP within the Aβ domain at the θ-site (between Phe19 and Phe20), effectively serving as an alternative α-secretase-like pathway that prevents Aβ peptide generation [57]. The most critical, physiologically validated substrate of BACE2 is premelanosome protein 17 (PMEL17, or PMEL), a transmembrane glycoprotein exclusively expressed in melanocytes [58]. BACE2-mediated cleavage of PMEL17 within the early endosomal compartment is a strict requirement for the formation of the fibrillar matrix within stage II melanosomes. This matrix is essential for the subsequent deposition and organization of melanin polymers [59].

Genetic ablation of BACE2 ($BACE2^{-/-}$) in murine models, or pharmacological inhibition of BACE2 using non-selective BACE1/2 inhibitors, completely disrupts melanosome maturation, leading to a marked block in melanin deposition [60]. Consequently, $BACE2^{-/-}$ mice exhibit a dramatic "coat color dilution" phenotype, characterized by hair depigmentation and retinal pigment epithelium abnormalities [61]. In clinical trials of non-selective BACE inhibitors, this mechanism manifested as a highly visible, dose-dependent hair depigmentation (vitiligo-like whitening of hair and skin) in human subjects, presenting a significant aesthetic and physiological liability [62].

2.3.3. Role in Pancreatic β-Cell Regulation

BACE2 also serves as a critical regulator of pancreatic β-cell homeostasis and systemic glucose tolerance [63]. The enzyme is highly expressed in pancreatic islet cells, where it cleaves transmembrane protein 27 (TMEM27), a collectrin-like glycoprotein that promotes β-cell proliferation and insulin secretion [64]. Cleavage of TMEM27 by BACE2 results in the shedding of its ectodomain, leading to its rapid degradation and clearance from the β-cell surface.

In vitro and *in vivo* studies indicate that BACE2-mediated degradation of TMEM27 controls β-cell mass; thus, genetic deletion of BACE2 or selective BACE2 inhibition can increase functional islet cell mass and improve glucose-stimulated insulin secretion [65]. Conversely, non-selective BACE inhibitors can interfere with these metabolic control systems, causing unpredictable fluctuations in systemic glucose levels and insulin sensitivity in patients with underlying metabolic vulnerabilities, further reinforcing the need for exquisite BACE1-specific selectivity [66].

2.4. Cathepsin D and Other Aspartyl Proteases

2.4.1. Lysosomal Localization and Metabolic Recycling

Cathepsin D (CatD) is a soluble, lysosomal aspartic protease synthesized as a 412-amino-acid precursor (pro-CatD) that is targeted to the lysosomal compartment via the mannose-6-phosphate receptor pathway [67]. Upon reaching the acidic environment of the lysosome, pro-CatD undergoes proteolytic processing to yield an active single-chain intermediate, which is further cleaved into a mature, double-chain form consisting of a light chain (approximately 14 kDa) and a heavy chain (approximately 34 kDa) linked by disulfide bonds [68]. CatD is highly abundant in almost all mammalian cells, particularly within the central nervous system, operating within a highly acidic pH range (pH 2.5–6.0) with maximal catalytic activity at pH 3.5 [69].

CatD is responsible for the bulk degradation of intracellular and endocytosed proteins, the recycling of exhausted macromolecular complexes, and the maintenance of cellular proteostasis [70]. It plays an indispensable role in autophagic clearance, degrading damaged organelles (such as mitochondria) and misfolded proteins (including α-synuclein, huntingtin, and hyperphosphorylated tau) [71]. CatD is a major mediator of the lysosome-initiated apoptotic pathway; under conditions of oxidative stress or lysosomal membrane permeabilization, CatD translocates into the cytosol, where it selectively cleaves Bid to initiate the mitochondrial apoptotic cascade [72].

2.4.2. Cross-Reactivity Mechanisms

Despite sharing only modest overall sequence identity with BACE1 (approximately 29% sequence identity and 46% sequence similarity), CatD exhibits high structural homology within the core catalytic fold [73]. X-ray crystallographic studies indicate that the spatial positioning of the active-site aspartic residues (Asp33 and Asp231 in CatD, corresponding to Asp32 and Asp228 in BACE1) is highly conserved [74].

Both enzymes accommodate peptide substrates via a similar network of hydrogen-bonding and hydrophobic interactions within the active-site cleft. Many first-generation, transition-state mimetic BACE1 inhibitors which feature core scaffold structures designed to mimic the tetrahedral transition state of peptide bond hydrolysis (such as statines, hydroxyethylamines, and norstatines) bind deeply within this conserved aspartic catalytic machinery [75]. Consequently, these early compounds exhibit potent, nanomolar cross-reactivity with CatD, rendering them highly non-selective and unsuitable for therapeutic application [76].

2.4.3. Pathological Outcomes of Lysosomal CatD Inhibition

The physiological consequences of cross-reactive CatD inhibition are severe and highly destructive. Complete genetic deficiency of CatD in mice results in a fatal phenotype characterized by progressive, severe neurodegeneration, lysosomal storage abnormalities, intractable seizures, and early death, closely recapitulating the human autosomal recessive lysosomal storage disease known as neuronal ceroid lipofuscinosis (NCL) [77].

Even partial pharmacological inhibition of CatD induces marked cellular pathology, most notably ocular toxicity [78]. High-resolution quantitative chemoproteomic profiling of experimental animals treated with non-selective BACE1/CatD inhibitors has shown that CatD blockade in the eye disrupts the autophagic degradation of photoreceptor outer segments within the retinal pigment epithelium (RPE) [79]. This leads to the toxic accumulation of lipofuscin-like autofluorescent aggregates within lysosomes, triggering RPE cell hypertrophy, retinal thinning, photoreceptor cell death, and progressive blindness [80].

Table 1. Comparative Biochemical and Physiological Profiles of BACE1, BACE2, and Cathepsin D

Parameter	BACE1	BACE2	Cathepsin D (CatD)
Primary Subcellular Localization	Trans-Golgi network, late endosomes, secretory vesicles	Plasma membrane, early endosomes, pancreatic islet cells	Lysosomal lumen, autophagosomes
Optimal catalytic pH range	3.5-5.5 (maximal at 4.5)	5.0-7.0 (broader, neutral tolerance)	2.5-5.0 (maximal at 3.5)
Sequence Identity with BACE1	100%	≈ 45% (≈ 64% similarity)	≈ 29% (≈ 46% similarity)
Active-Site Structural Features	Flexible 10s loop; expandable S3 subsite containing Ile110	Rigid 10s loop; constrained S3 subsite containing Val110	Soluble active-site cleft; absence of flexible gatekeeper flap
Primary Physiological Substrates	APP, NRG1 (Type I/III), Sez6, CHL1, Navbeta2, Contactin-2	PMEL17 (PMEL), TMEM27, IAPP, APP (θ-site cleavage)	Intracellular/endocytosed proteins, α-synuclein, tau, Bid
Key Physiological Functions	Myelination, synaptic plasticity, axonal guidance, dendritic spine density	Melanosome biogenesis, pancreatic β-cell proliferation	Lysosomal proteostasis, metabolic recycling, apoptotic cascade mediator
Knockout Phenotype (Murine)	Hypomyelination, seizure susceptibility, impaired LTP, memory deficits	Coat color dilution, retinal depigmentation	Fatal neurodegeneration, lysosomal storage disease, early death
Inhibition Toxicity (Clinical/Animal)	Paradoxical cognitive decline, synaptic loss, neuropsychiatric symptoms	Hair depigmentation, vitiligo, glucose metabolic imbalances	Retinal pigment epithelium degeneration, photoreceptor loss, retinopathy

The withdrawal of several highly promising clinical BACE1 candidates (such as LY2811376 and AMG-8718) during early-phase studies was necessitated by the discovery of such retinal toxicities and RPE abnormalities in preclinical species, highlighting CatD selectivity as a non-negotiable safety criterion in BACE1 inhibitor design [81].

3. Molecular and Chemical Strategies to Achieve Selectivity

The development of small-molecule inhibitors targeting β-site amyloid precursor protein cleaving enzyme 1 (BACE1) has transitioned through distinct chemical paradigms, driven by the need to balance blood-brain barrier (BBB) penetration with high selectivity against structurally related aspartyl proteases [82]. Early design efforts relied heavily on classic peptidomimetic approaches, whereas modern discovery pipelines leverage non-peptidic scaffolds, conformational restriction, and advanced computational algorithms to achieve precise molecular recognition [83].

3.1. Structure-Based Drug Design and Active-Site Mapping

3.1.1. Target Subsite Optimization and Transition-State Mimicry

The historical foundation of BACE1 inhibitor design was built upon transition-state mimetics that sought to replicate the tetrahedral intermediate formed during the hydrolysis of the peptide bond in the amyloid precursor protein (APP) [84]. The earliest iterations utilized non-cleavable core structures, such as statines, hydroxyethylamines (HEAs), and norstatines, which feature a stable hydroxyl group that establishes direct, bidentate hydrogen bonds with the catalytic aspartyl dyad (Asp32 and Asp228) [85]. While these peptidomimetic HEA derivatives achieved high affinity, their clinical utility was severely limited by their high molecular weight, large polar surface area, and poor brain-to-plasma partition coefficients, alongside their susceptibility to active efflux by P-glycoprotein (P-gp) [86].

To address these pharmacokinetic deficiencies, medicinal chemists turned to non-peptidic, small-molecule templates characterized by cyclic imine cores [87]. Scaffolds such as aminofurans, aminoimidazoles, iminopyrimidines, and aminothiazines emerged as highly efficient catalytic anchors [88]. The exocyclic amino group of these structures, when protonated at physiological pH, forms a stable, salt-bridge-like electrostatic network with the carboxylate side chains of both Asp32 and Asp228 [89]. By securing this core interaction, structural modifications could be directed outward into the adjacent S 1, S2, S3, and S 1' subsites to systematically optimize both affinity and selectivity [90].

For example, extending hydrophobic substituents into the S 1 pocket which is lined by hydrophobic residues such as Leu30, Phe108, and Ile118 significantly stabilizes the ligand-receptor complex through favorable van der Waals interactions [91]. Concurrently, the introduction of polar or weakly basic moieties that project toward the S2 subsite allows for the formation of hydrogen bonds with the backbone amide groups of Asp223 and Ser224, thereby discriminating BACE1 from the highly hydrophobic active cleft of pepsin [92].

3.1.2. Water-Mediated Hydrogen Bonding Networks

High-resolution X-ray crystallographic studies have revealed that the BACE1 active site contains several highly conserved, structurally rigid water molecules that play crucial roles in ligand binding and catalytic activity [93]. One of the most significant water molecules, denoted as the catalytic water (Wc), is coordinated directly between the carboxylate groups of Asp32 and Asp228 in the apo state, but is displaced upon the binding of transition-state mimetics [94].



Figure 3. Downstream On-Target and Off-Target Toxicology of BACE1 Inhibitors

In addition to Wc, a highly ordered network of structural water molecules occupies the region surrounding the S2 and S2' subsites [95]. In BACE1, a specific conserved water molecule (W2) bridges the interaction between the flexible flap region (specifically the backbone carbonyl of Tyr71) and the floor of the active cleft [96]. Medicinal chemistry strategies have successfully exploited this network by designing inhibitors with precise hydrogen-bonding acceptors (such as carbonyl, sulfonyl, or urea groups) that either structuralize or displace these water molecules [97].

Table 2. Structural Characteristics and Selectivity Mechanisms of Representative BACE1 Inhibitor Classes

Inhibitor Class / Scaffolds	Representative Candidates	Primary Structural Anchoring Mechanism	Selectivity Optimization Focus	Primary Advantages	Major Safety or Pharmacokinetic Liabilities
Peptidomimetic Transition-State Mimetics	OM99-2, LY2811376, OM00-3	Statine, HEA, or norstatine cores forming bidentate hydrogen bonds with Asp32/Asp228	Hydrophobic extensions into the S1 and S1' pockets	Exceptional *in vitro* potency (IC50 < 10 nM)	High molecular weight, poor blood-brain barrier penetration, active P-gp efflux, low Cathepsin D selectivity
Non-Peptidic Cyclic Imines (First Generation)	Aminofurans, Early Aminoimidazoles	Monoprotonated exocyclic amine establishing a salt bridge with the catalytic dyad carboxylates	Projecting bulky hydrophobic rings to contact the outer S3 subsite	Reduced peptide character, improved lipophilicity	Moderate brain penetration, persistent hERG channel inhibition risks, off-target peripheral metabolic pathways
Non-Peptidic Cyclic Imines (Second Generation)	Verubecestat, Lanabecestat, Umibecestat	Iminopyrimidines, aminothiazines, or 3-imino-1,2,4-thiadiazinane 1,1-dioxides	Exploitation of the Gln73 flap charge and Ile110 pocket differences	High Kp,uu,brain, strong BACE2 and Cathepsin D safety margins	On-target toxicity at high doses due to over-depletion of Sez6 and NRG1
Macrocyclic Scaffolds	Macrocyclic Peptidomimetics, Cyclic Sulfone HEAs	Pre-organized rigid ring locking the bioactive conformation within the catalytic cleft	Conformational restriction fitting the specific dimensions of the BACE1 active cleft	Minimized entropic loss upon binding ($\Delta S > 0$), high metabolic stability	Synthetic complexity, limited chemical tractability for high-throughput modifications

Displacing a highly ordered, trapped water molecule into the bulk solvent provides a substantial thermodynamic driving force by increasing the translational and rotational entropy of the system (ΔS binding > 0) [98]. Conversely, designing functional groups that establish optimal, water-mediated hydrogen-bonding bridges with W 2 stabilizes the closed conformation of the flap, securing the ligand in the active site with high enthalpic efficiency (ΔH binding ≤ 0) [99]. Because the spatial distribution and thermodynamic stability of these water networks differ between BACE1 and Cathepsin D, tailoring the water-displacement properties of candidate molecules represents an effective method for achieving high Cathepsin D selectivity [100].

3.2. Exploiting Structural Divergences Between BACE1 and BACE2

3.2.1. S3 Subsite Plasticity and the 10s Loop

Despite the 64% sequence similarity between BACE1 and BACE2, target selectivity can be achieved by exploiting subtle, dynamic structural divergences in their respective substrate-binding pockets [101]. The most significant of these divergences occurs within the S3 subsite, which is shaped by a highly flexible loop region known as the 10s loop (spanning residues Gly11 to Lyr15 in BACE1) [102].

In BACE1, the 10s loop exhibits high conformational plasticity, allowing the S3 pocket to expand significantly to accommodate bulky, rigid hydrophobic substituents [103]. Conversely, in BACE2, the corresponding loop is structurally constrained and sterically rigid, resulting in a significantly smaller and less adaptable S3 subsite [104].

Medicinal chemistry programs have exploited this pocket-size disparity by designing inhibitors containing large, rigid biaryl or bicyclic P3 groups [105]. When these compounds bind to BACE1, the 10s loop undergoes a conformational displacement that opens the S3 subsite, facilitating stable hydrophobic packing and high-affinity binding [106]. When the same compounds attempt

to bind BACE2, the rigid, unyielding nature of the BACE2 S3 pocket results in severe steric clash and a marked reduction in binding affinity [107]. This structural strategy was successfully employed in the development of the selective clinical candidate umibecestat, which achieved a greater than 100-fold selectivity margin for BACE1 over BACE2 [108].

3.2.2. Residue Divergence at the main Subsites

Beyond loop dynamics, specific amino acid variations within the binding subsites provide critical anchor points for selective ligand design [109]. Within the S3 pocket, BACE1 features an isoleucine residue at position 110 (Ile110), whereas BACE2 possesses a valine residue at the homologous position (Val110) [110]. Although this represents a difference of only a single methyl group, the altered local topology can be targeted using highly customized hydrophobic shapes [111].

The electrostatic environment of the S2 and S2' subsites differs between the two enzymes [112]. BACE1 contains a polar glutamine residue at position 73 (Gln73) on the flap, while BACE2 features a basic lysine residue (Lys73) at the equivalent site [113]. This charge divergence can be exploited by introducing weakly acidic or neutral hydrogen-bonding groups into the P2 position of the inhibitor [114]. These groups establish favorable polar interactions with the amide side chain of Gln73 in BACE1, but experience electrostatic repulsion or unfavorable desolvation penalties when interacting with the positively charged Lys73 in BACE2, thereby driving the selectivity toward BACE1 [115].

3.3. Conformational Restriction via Macrocyclization

3.3.1. Entropy Reduction and Pre-organized Scaffolds

Macrocyclization is an established strategy in medicinal chemistry to lock a flexible molecule into its bioactive conformation prior to target binding [116]. For BACE1, where the active site is elongated and requires the ligand to span multiple subsites, acyclic inhibitors typically undergo a significant loss of conformational entropy ($\Delta S_{binding} \leq 0$) upon binding, as multiple freely rotatable bonds are immobilized within the catalytic pocket [117].

By covalently linking two distal parts of the inhibitor (such as the P1 and P3 substituents, or the P1 and P1' side chains) to form a macrocyclic ring, the molecule is pre-organized into its active conformation [118]. This structural pre-organization minimizes the entropic penalty associated with target binding, which can translate into a substantial increase in thermodynamic binding affinity ($\Delta G_{binding} = \Delta H - T\Delta S$) [119].

Macrocycles often exhibit improved metabolic stability, as the rigidified peptide-like backbone is less susceptible to proteolytic cleavage and oxidative metabolism by cytochrome P450 enzymes (CYP3A4) [120].

3.3.2. Shape Complementarity and Subsite Discrimination

Macrocycles also offer distinct selectivity advantages [121]. Because the macrocyclic ring introduces rigid, well-defined three-dimensional contours, its binding is highly sensitive to the exact spatial geometry of the target cleft [122]. A macrocycle tailored to fit the BACE1 active site will exhibit high shape complementarity, establishing optimal hydrophobic contacts and hydrogen-bonding networks across multiple subsites simultaneously [123].

However, because the active-site dimensions and loop flexibilities of BACE2 and Cathepsin D differ slightly, these off-target proteases cannot easily deform their catalytic clefts or accommodate the rigid, non-compliant shape of the BACE1-optimized macrocycle [124]. Consequently, macrocyclic inhibitors can achieve exceptional selectivity margins over related proteases, effectively exploiting topological differences that acyclic compounds, with their high conformational adaptability, cannot differentiate [125].

3.4. Fragment-Based Drug Design (FBDD)

3.4.1. Identification of Novel Anchoring Chemotypes

Fragment-based drug design (FBDD) has emerged as a powerful alternative to high-throughput screening (HTS) for BACE1, offering an efficient route to explore vast chemical space [126]. FBDD involves screening libraries of very small, low-molecular-weight compounds (molecular weight < 250 Da, typically containing 10 to 15 heavy atoms) that exhibit low binding affinity (millimolar to high micromolar range) but possess high ligand efficiency [127].

These fragment screens are monitored using highly sensitive biophysical techniques, including nuclear magnetic resonance (NMR) spectroscopy (such as saturation transfer double difference, STD-NMR), surface plasmon resonance (SPR), and high-throughput X-ray crystallography [128].

In the context of BACE1, FBDD screening succeeded in identifying non-acidic catalytic anchors that avoid the highly polar, peptide-like configurations of early transition-state mimetics [129]. Fragments based on novel imino-heterocyclic cores, such aS2-aminobenzimidazoles and dihydrothiazines, were discovered to bind directly to the catalytic dyad while maintaining excellent physicochemical properties suitable for further optimization [130].

3.4.2. Structure-Guided Fragment Growth and Merging

Once a promising fragment hit is identified and its binding orientation is validated via co-crystallization, structure-guided optimization is performed to grow or merge the fragment into adjacent subsites [131]. Because the starting fragments are small, they occupy only a fraction of the BACE1 catalytic cleft, leaving ample room for the systematic introduction of functional groups that target BACE1-specific structural features [132].

For example, a low-affinity aminothiazine fragment anchoring the aspartyl dyad can be structurally expanded by projecting a fluorinated phenyl group into the S 1 pocket, followed by the addition of a nitrogen-containing heterocycle directed toward the S2 or S3 subsite [133]. This stepwise growth is continuously guided by high-resolution X-ray structures, ensuring that every atom added contributes to both potency and selectivity [134].

By optimizing the ligand's fit within the distinct subsites of BACE1 from the earliest stages of design, FBDD avoids the off-target liabilities that frequently arise when attempting to retroactively engineer selectivity into large, non-selective leads identified through traditional HTS [135].

3.5. Advanced Computational and In Silico Optimization

3.5.1. Molecular Dynamics Simulations and Free Energy Perturbation

Modern computational chemistry has become indispensable for accelerating the design of selective BACE1 inhibitors [136]. Static crystal structures represent only a snapshot of the enzyme-ligand complex, whereas molecular dynamics (MD) simulations allow researchers to observe the structural fluctuations of BACE1 in a simulated physiological environment [137]. MD simulations are particularly valuable for modeling the dynamic movements of the Val69–Tyr71 flap and the 10s loop, providing insights into how different chemical modifications affect the conformational stability of these regions [138].

Free energy perturbation (FEP) and thermodynamic integration (TI) calculations are increasingly used to quantitatively predict the binding free energy (ΔG) of prospective compounds before chemical synthesis [139]. By computationally perturbing a specific atom or functional group of a ligand in both BACE1 and BACE2 virtual environments, FEP can estimate the selectivity ratio (IC 50 BACE2 / IC 50 BACE1) with high accuracy (often within 1 kcal/mol of experimental values) [140]. This predictive capability enables medicinal chemists to prioritize the most selective candidates for synthesis, reducing the time and cost associated with empirical optimization cycles [141].

3.5.2. Machine Learning and Multi-Parameter Optimization

The integration of artificial intelligence (AI) and machine learning (ML) has further refined the design process [142]. Deep neural networks and support vector machines are trained on massive biochemical datasets (such as those compiled in ChEMBL) containing historical BACE1, BACE2, and Cathepsin D inhibition data [143]. These models can learn complex, non-linear relationships between molecular descriptors and protease selectivity, enabling the virtual screening of millions of virtual compounds in a fraction of the time required for traditional assays [144].

Importantly, ML is utilized in multi-parameter optimization (MPO) frameworks to simultaneously balance multiple competing endpoints [145]. An ideal BACE1 inhibitor must possess high potency and selectivity, but it must also exhibit optimal blood-brain barrier permeability, low susceptibility to P-glycoprotein-mediated efflux, high metabolic stability, and minimal hERG ion channel inhibition [146].

By utilizing generative chemistry models coupled with MPO scoring functions, researchers can design compounds that satisfy these pharmacokinetic and selectivity criteria, avoiding the late-stage developmental failures that plagued earlier generations of BACE1 inhibitors [147].

4. Selectivity Assessment

To support medicinal chemistry efforts, drug discovery pipelines must implement robust, standardized testing protocols capable of accurately quantifying selectivity margins across multiple biological levels [148]. This requires a combination of high-precision *in vitro* biochemical assays, functional cellular models, broad-spectrum proteomic profiling, and integrated pharmacokinetic modeling [149].

4.1. *In vitro* Enzymatic Profiling

4.1.1. Fluorogenic and Luminescent Kinetic Assays

The primary quantification of inhibitor potency is performed using *in vitro* biochemical assays utilizing purified, recombinant human enzymes [150]. These assays typically rely on fluorescence resonance energy transfer (FRET) technology, where a synthetic peptide substrate mimicking the BACE1 cleavage site is labeled with a donor fluorophore at one terminus and an acceptor quencher at the opposite terminus [151]. In the intact peptide, the proximity of the quencher suppresses the fluorescence of the donor. Upon proteolytic cleavage of the scissile peptide bond by BACE1, the donor and quencher drift apart, resulting in a measurable increase in fluorescence intensity over time [152].

Commonly utilized substrates include peptides containing the Swedish mutation sequence (Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Arg, or SEVNLDAEFK), which BACE1 cleaves with approximately 10-fold higher catalytic efficiency (k cat/K m) than the wild-type APP sequence, thereby improving assay sensitivity [153].

Crucial to the accuracy of these assays is the precise control of the reaction conditions. BACE1 exhibits optimal catalytic activity under acidic conditions (pH 4.0–5.0), which mimics the microenvironment of endosomes and lysosomes [154]. However, because Cathepsin D operates at an even lower pH optimum (pH 3.0–3.5) and BACE2 displays a broader, more neutral pH tolerance, comparative enzymatic profiling must be carefully calibrated to ensure that differences in measured IC 50 values represent true differences in binding affinity rather than experimental artifacts induced by sub-optimal pH conditions [155].

4.1.2. Kinetic Resolution and Standardized Parameterization

While IC 50 values provide a convenient metric for preliminary compound ranking, they are highly dependent on experimental variables, including enzyme concentration, substrate concentration, and incubation time [156]. Consequently, comparing IC 50 values across different laboratories can lead to erroneous conclusions regarding selectivity margins [157]. To establish a more rigorous biophysical standard, drug discovery programs prioritize the determination of the absolute inhibitory constant (K i) or the dissociative constant (K d) through detailed kinetic analysis [158].

By measuring initial reaction rates over a range of substrate and inhibitor concentrations, researchers can determine whether a compound exhibits competitive, non-competitive, or uncompetitive inhibition mechanisms, allowing for the mathematical calculation of K_i using the Cheng-Prusoff equation [159]:

$$K_i = \frac{IC_{50}}{1 + \frac{[S]}{K_m}}$$

Where [S] is the substrate concentration and K_m is the Michaelis constant of the substrate for the enzyme.

Because BACE1 inhibitors can exhibit slow-binding kinetics (where the establishment of the enzyme-inhibitor equilibrium requires several minutes or hours), real-time kinetic monitoring is necessary to capture accurate association (k_{on}) and dissociation (k_{off}) rate constants [160]. Compounds with exceptionally slow dissociation rates (long target residence time, $\tau = 1/k$ off) can provide prolonged pharmacodynamic efficacy *in vivo*, even after systemic drug concentrations have declined, which represents an important parameter to balance against potential toxicity risks [161].

4.2. Cell-Based Functional Characterization

4.2.1. Cellular APP Processing and Aβ Secretion Dynamics

Although purified enzyme assays provide precise biophysical data, they lack the complex cellular environment where BACE1 naturally operates [162]. To bridge this gap, candidate inhibitors are evaluated in cell-based assays using human cell lines (such as

human embryonic kidney HEK293 cells or neuroblastoma SH-SY5Y cells) stable-transfected with human APP, typically carrying the Swedish mutation (APP swe) to ensure high baseline levels of Aβ secretion [163]. In these assays, cells are treated with varying concentrations of the inhibitor for a defined incubation period (typically 24 to 48 hours) [164]. The conditioned cell culture media is subsequently harvested to quantify secreted proteolytic fragments [165]. The primary readout for BACE1 efficacy is the reduction of secreted Aβ 40 and Aβ 42 peptides, alongside the soluble cleavage product sAPPβ, which are measured using highly sensitive sandwich Enzyme-Linked Immunosorbent Assays (ELISA) or Homogeneous Time-Resolved Fluorescence (HTRF) technologies [166].

Concurrently, levels of sAPPα (the product of α-secretase cleavage) are monitored; an effective BACE1 inhibitor should drive a reciprocal increase in sAPPα secretion as APP is shunted from the amyloidogenic to the non-amyloidogenic pathway, confirming target-specific functional modulation [167].

4.2.2. Endogenous Substrate Processing in Neuronal Systems

To evaluate the potential for on-target toxicity resulting from the depletion of alternative physiological substrates, selectivity cascades incorporate primary neuronal cultures or human induced pluripotent stem cell (iPSC)-derived cortical neurons [168]. These physiologically relevant models express endogenous levels of BACE1 along with its key neuronal substrates, including Seizure Protein 6 (Sez6) and Neuregulin-1 (NRG1) [169].

Using western blot analysis or high-content imaging, researchers monitor the accumulation of uncleaved, full-length substrate proteins within the neuronal membrane, alongside the corresponding decrease in shed ectodomains within the culture supernatant [170].

A highly selective BACE1 inhibitor designed for clinical translation should show a therapeutic window, it must robustly inhibit the cleavage of APP to lower Aβ levels while sparing, or only partially inhibiting, the processing of Sez6 and NRG1 [171].

Achieving this cellular selectivity often depends on exploiting differences in sub-cellular trafficking; because APP is cleaved primarily within endosomes while NRG1 and Sez6 undergo significant processing at the plasma membrane or in secretory vesicles, compounds that partition into specific intracellular compartments can achieve functional selectivity in living neurons that cannot be predicted by cell-free biochemical assays alone [172].

4.3. Broad-Spectrum Off-Target Profiling

4.3.1. Chemoproteomic Profiling and Active-Site Directed Probes

To confirm that an inhibitor does not engage unexpected cellular targets in native tissues, advanced drug discovery programs utilize quantitative chemoproteomic profiling [173]. This methodology employs activity-based probes (ABPs) small-molecule inhibitors modified with a photoreactive cross-linking group (such as a diazirine) and a click-chemistry handle (such as an alkyne) to covalently label active enzymes within native tissue lysates (e.g., human or rodent brain homogenates) [174]. In a typical competitive chemoproteomic experiment, the brain lysate is pre-incubated with varying concentrations of the unlabeled clinical candidate, followed by treatment with the ABP [175]. The candidate compound competes with the probe for binding to the active sites of BACE1 and any related proteases present in the complex biological mixture.

Following photo-irradiation to induce covalent cross-linking, the labeled proteins are coupled to biotin-azide via copper-catalyzed click chemistry, enriched on streptavidin beads, digested with trypsin, and analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) [176]. This multiplexed approach allows for the simultaneous quantification of target engagement across the entire active proteome, providing a direct readout of the compound's selectivity margin under native conditions and identifying any unexpected, non-aspartic protease off-targets early in development [177].

4.3.2. Panel Screening Against Related Aspartyl Proteases

In addition to native tissue profiling, candidate compounds are routinely evaluated against a defined panel of purified, recombinant human aspartyl proteases to construct an off-target safety profile [178]. This panel typically includes:

- Cathepsin E (CatE): A major intracellular aspartic protease involved in antigen processing and presentation; its systemic inhibition can lead to immune dysfunction [179].
- Renin: A highly specific renal aspartic protease that regulates the renin-angiotensin-aldosterone system; inadvertent inhibition of renin can cause hypotension and electrolyte imbalances [180].

- Pepsin A and Gastricsin: Soluble digestive proteases in the stomach; cross-reactivity can lead to severe gastrointestinal distress and mucosal irritation [181].

Quantifying the selectivity index (the ratio of the off-target enzyme IC 50 to the BACE1 IC 50) across this panel ensures that only molecules with clean systemic safety profiles are selected for *in vivo* evaluation [182]. Most modern pipelines set a minimum selectivity threshold of 1000-fold over renin and pepsin to completely eliminate cardiovascular and digestive safety concerns [183].

4.4. Pharmacokinetic and Pharmacodynamic (PK/PD) Integration

4.4.1. Blood-Brain Barrier Permeability and Brain-to-Plasma Partitioning

For a BACE1 inhibitor to be therapeutically viable, it must cross the blood-brain barrier (BBB) and reach the interstitial space of the brain parenchyma where neuronal APP cleavage occurs [184]. The physical barrier of the BBB, characterized by tight junctions between brain capillary endothelial cells, restricts the passive diffusion of highly polar or high-molecular-weight molecules [185]. The active efflux transporters P-glycoprotein (P-gp, encoded by the ABCB1 gene) and Breast Cancer Resistance Protein (BCRP, encoded by the ABG2 gene) actively pump lipophilic amine-containing drugs out of the endothelial cells back into the systemic circulation [186].

During preclinical PK studies in rodents, the total brain-to-plasma concentration ratio (K_p) is calculated [187]:

$$K_p = \frac{C_{brain}}{C_{plasma}}$$

However, because drug molecules can bind extensively to myelin and other brain lipids, the total brain concentration (C_{brain}) does not reflect the pharmacologically active fraction [188]. Medicinal chemistry efforts prioritize the determination of the unbound brain-to-plasma partition coefficient (K p,uu,brain), which represents the ratio of the concentration of free, unbound drug in the brain interstitial fluid ($C_{u,brain}$) to that in the unbound systemic plasma ($C_{u,\ plasma}$) [189]:

$$K_{p,uu,brain} = \frac{C_{u,brain}}{C_{u,plasma}} = \frac{f_{u,brain} \cdot C_{brain}}{f_{u,plasma} \cdot C_{plasma}}$$

Where $f_{u,brain}$ and $f_{u,plasma}$ represent the unbound fractions in brain and plasma tissue, respectively [190].

A compound that is not a substrate for active efflux transporters will exhibit a $K_{p,uu,brain}$ close to 1.0, ensuring that the therapeutic target in the central nervous system (CNS) is fully engaged without requiring high systemic doses that could trigger peripheral toxicities [191].

4.4.2. Tissue Distribution and Retinal Compartmentalization

The risk of off-target toxicity is also heavily influenced by the compound's sub-cellular partitioning and tissue-specific accumulation [192]. Highly lipophilic basic compounds (with a high log D at pH 7.4 and a basic pK a > 8) can undergo lysosomal entrapment, also known as lysosomotropism [193]. In this process, the uncharged form of the drug passively diffuses across the lysosomal membrane into the highly acidic lysosomal lumen (pH ≈ 4.5), where it becomes protonated [194]. Once protonated, the positively charged drug molecule can no longer cross the lipid bilayer, leading to its accumulation at concentrations up to 1000-fold higher than those in the cytosol [195].

This lysosomal accumulation is highly pronounced within the retinal pigment epithelium (RPE) of the eye, which is packed with lysosome-rich, phagocytic machinery [196]. If a BACE1 inhibitor possesses even moderate cross-reactivity with Cathepsin D, lysosomal trapping within the RPE can raise local drug concentrations above the threshold required to fully block Cathepsin D function, triggering autophagic failure and retinal degeneration [197].

Consequently, PK/PD modeling must incorporate tissue distribution studies to track the spatial partitioning of candidates in the retina, skin, and pancreas, ensuring that the local unbound concentrations in these peripheral organs remain well below the safety thresholds established by *in vitro* profiling [198].

Table 3. Methodologies for Quantifying BACE1 Selectivity and Target Engagement

Methodology	Primary Assay Configuration	Parameters Measured	Application	Advantages	Limitations
In vitro FRET Assays	Recombinant human BACE1, BACE2, or CatD incubated with peptide substrates containing the Swedish mutation	IC50 (half-maximal inhibitory concentration), Ki (absolute inhibitory constant)	High-throughput screening and early-stage lead optimization	Precise, cell-free biophysical resolution; high reproducibility	Lacks biological context, fails to account for cell permeability or active efflux
Cellular Processing Assays	APP-transfected cell lines (HEK293, SH-SY5Y) or primary cortical neurons	Secreted levels of Aβ40, Aβ42, sAPPβ, and sAPPα	Verification of cellular target engagement and non-amyloidogenic pathway shunting	Incorporates membrane permeability and dynamic physiological context	High assay-to-assay variability; potential confounding cellular toxicity
Endogenous Substrate Cleavage Tracking	Primary cortical neurons or iPSC-derived human neurons treated with candidate molecules	Western blot or ELISA quantification of full-length vs. cleaved Sez6, NRG1, and CHL1	On-target safety assessment to establish therapeutic windows	Directly measures neurophysiologically critical pathways	Complex culture protocols; lower throughput than standard cell lines
Chemoproteomic Profiling	Competitive binding of activity-based probes (ABPs) in native human or rodent brain lysates	Percent active-site displacement across the complete aspartyl protease proteome	Broad-spectrum off-target verification in complex native tissues	Unbiased, proteome-wide selectivity analysis under native conditions	Requires specialized probe synthesis and advanced LC-MS/MS setups
In vivo PK/PD Modeling	Animal tissue harvesting (plasma, CSF, brain parenchyma) following drug administration	$K_{p,uu,brain} = \frac{C_{u,brain}}{C_{u,plasma}}$, and CSF Aβ depletion kinetics	Determination of the *in vivo* therapeutic index	Integrates systemic distribution, clearance, and blood-brain barrier transport	High inter-species variability (rodent to human translation hurdles)

5. Clinical Trials

The clinical translation of small-molecule β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors represents one of the most complex chapters in modern neuropharmacology [199]. Despite demonstrating robust, dose-dependent target engagement and achieving the primary biochemical goal of lowering amyloid-β (Aβ) levels in human subjects, every candidate that entered Phase II or Phase III trials was ultimately discontinued [200]. These failures have forced a fundamental re-evaluation of the timing, dosing, and physiological boundaries of BACE1 inhibition [201].

5.1. Clinical Profile of Discontinued Candidates

5.1.1. Verubecestat (MK-8931) and the EPOCH/APEC Trials

Verubecestat, a highly potent, non-peptidic cyclic imine BACE1/2 inhibitor developed by Merck, was evaluated in two large-scale, randomized, double-blind, placebo-controlled Phase III trials [202]. The EPOCH trial enrolled 1,958 patients with mild-to-moderate Alzheimer's disease (AD), evaluating daily doses of 12 mg and 40 mg [203].

Although verubecestat achieved greater than 80% reduction in cerebrospinal fluid (CSF) Aβ 40, Aβ 42, and soluble β-amyloid precursor protein (sAPPβ) concentrations, the trial was terminated early in February 2017 for futility [204]. Treated patients showed no stabilization of cognitive or functional decline; instead, they exhibited a dose-dependent, statistically significant worsening on the Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADAS-Cog) compared to those receiving the placebo [205].

Concurrently, the APEC trial, which evaluated verubecestat in 1,454 patients with prodromal AD, was halted in February 2018 [206]. Similar to the EPOCH results, prodromal patients treated with verubecestat showed accelerated cognitive decline,

accompanied by a higher incidence of adverse events, including sleep disturbances, neuropsychiatric symptoms (anxiety, depression, agitation), hair depigmentation, and significant weight loss [207].

5.1.2. Lanabecestat (AZD3293) and the AMARANTH/DAYBREAK-ALZ Programs

Lanabecestat, developed jointly by AstraZeneca and Eli Lilly, is a slow-binding, high-affinity BACE1/2 inhibitor [208]. It was advanced into two global Phase III trials: AMARANTH, which enrolled 2,218 patients with early AD (mild cognitive impairment or mild AD dementia), and DAYBREAK-ALZ, which evaluated 1,722 patients with mild AD dementia [209].

In June 2018, both trials were discontinued following an interim analysis by an independent data monitoring committee, which concluded that lanabecestat was highly unlikely to meet its primary efficacy endpoints (slowing decline on the ADAS-Cog13 and the Clinical Dementia Rating–Sum of Boxes [CDR-SB]) [210].

Although lanabecestat was generally well-tolerated and did not trigger the acute safety concerns observed with other candidates, patients on both low (20 mg) and high (50 mg) daily doses showed a steady, dose-dependent decline in cognitive scores, confirming that robust central Aβ depletion alone does not translate to clinical efficacy once neuropathology is established [211].

5.1.3. Atabecestat (JNJ-54861911) and the EARLY Trial

Atabecestat, developed by Janssen, was designed as a highly potent BACE1 inhibitor with favorable brain penetration [212]. It was evaluated in the EARLY Phase II/III trial, which targeted 557 asymptomatic, cognitively normal older adults who were biomarker-positive for brain amyloid accumulation, representing a true secondary prevention paradigm [213].

However, in May 2018, Janssen voluntarily suspended dosing of atabecestat across all clinical trials due to safety concerns [214]. A substantial cohort of treated participants developed severe, idiosyncratic elevations in hepatic transaminases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]), indicating a risk of drug-induced liver injury [215].

Neuropsychiatric assessments revealed early-onset cognitive worsening, gait instability, and neuropsychiatric symptoms that resolved only after drug discontinuation, underscoring that even pre-symptomatic, amyloid-positive individuals are susceptible to the adverse functional consequences of intensive BACE1 blockade [216].

5.1.4. Umibecestat (CNP520) and the Generation Program

Umibecestat, developed by Novartis and Amgen, was engineered to exhibit improved selectivity for BACE1 over BACE2 (>3-fold) and Cathepsin D (>2000-fold) [217]. It was advanced into the ambitious Generation Study 1 and Generation Study 2 programs, which enrolled cognitively healthy older adults (aged 60 to 75) carrying the apolipoprotein E (APOE) ε4 allele, a major genetic risk factor for AD [218].

In July 2019, the Generation program was halted [219]. Despite its improved selectivity profile, participants treated with umibecestat showed a statistically significant worsening in cognitive scores (using the Repeatable Battery for the Assessment of Neuropsychological Status [RBANS]) as early as three months after initiating therapy [220].

Additionally, high-resolution magnetic resonance imaging (MRI) scans revealed a rapid, dose-dependent decrease in total brain volume and an accelerated loss of hippocampal volume in the active treatment groups [221]. These structural changes were accompanied by a compensatory increase in ventricular volume, indicating that high-dose, long-term BACE1 inhibition can lead to accelerated brain atrophy, possibly due to synaptic pruning or myelin thinning [222].

5.2. Biomarker Signatures and Target Engagement Dynamics

5.2.1. Amyloid-β Depletion Profiles in Cerebrospinal Fluid and Plasma

The pharmacodynamic evaluation of all clinical BACE1 inhibitors consistently showed rapid, profound, and sustained reductions in the levels of pathogenic Aβ species [223]. In human CSF, verubecestat, lanabecestat, and umibecestat achieved dose-dependent reductions of Aβ 38, Aβ 40, and Aβ 42 exceeding 75-90% relative to baseline [224]. A similar depletion profile was observed in systemic plasma, confirming highly effective, continuous target engagement both centrally and peripherally [225].

However, post-hoc analyses of these biomarker profiles revealed that such extreme depletion of Aβ was highly correlated with the onset of cognitive worsening [226]. Lowering Aβ below a physiological threshold may disrupt the normal signaling functions of the

peptide, as low picomolar concentrations of monomeric Aβ 42 are required to maintain long-term potentiation and facilitate synaptic vesicle release [227].

Table 4. Clinical Development Profiles and Outcomes of High-Profile Discontinued BACE1 Inhibitors

Candidate Name (Sponsor)	Primary Target Selectivity Profile	Phase / Trial Names	Patient Cohort	Central Target Engagement (Aβ Lowering)	Primary Clinical Failure Mode / Reason for Discontinuation	Adverse Events Observed
Verubecestat / MK-8931 (Merck)	BACE1/2 inhibitor; poor selectivity over BACE2	Phase III: EPOCH and APEC	Mild-to-moderate AD (N=1,958); Prodromal AD (N=1,454)	>80-90% reduction in CSF Aβ40 and Aβ42	Futility; treated patients exhibited accelerated, dose-dependent cognitive decline	Neuropsychiatric symptoms, sleep disturbances, hair depigmentation, weight loss
Lanabecestat / AZD3293 (AstraZeneca / Eli Lilly)	Slow-binding, high-affinity BACE1/2 inhibitor	Phase III: AMARANTH and DAYBREAK-ALZ	Early AD (N=2,218); Mild AD dementia (N=1,722)	Robust, sustained reduction in central and peripheral Aβ levels	Futility; lack of efficacy in halting cognitive decline (measured by ADAS-Cog13 and CDR-SB)	Generally well-tolerated, but showed a steady cognitive decline equivalent to placebo or worse
Atabecestat / JNJ-54861911 (Janssen)	Highly potent BACE1 inhibitor; favorable brain penetration	Phase II/III: EARLY	Asymptomatic, cognitively normal older adults positive for brain amyloid (N=557)	Robust target engagement in the central nervous system	Safety concerns; severe hepatic transaminase (ALT/AST) elevations	Idiosyncratic liver injury risk, early-onset cognitive worsening, gait instability
Umibecestat / CNP520 (Novartis / Amgen)	Engineered selectivity for BACE1 (>3-fold over BACE2, >2000-fold over CatD)	Phase III: Generation Study 1 and Generation Study 2	Cognitively healthy older adults carrying the APOEε4 risk allele	High-level central target engagement	Negative benefit-risk ratio; early cognitive worsening and brain structure loss	Statistically significant worsening in RBANS scores; rapid, dose-dependent decrease in total brain and hippocampal volumes

5.2.2. Reciprocal Changes in Soluble Amyloid Precursor Protein Ectodomains

To confirm that the observed reduction in Aβ was mediated specifically by BACE1 inhibition rather than non-specific clearance mechanisms, clinical protocols tracked the levels of soluble APP ectodomains [228]. Treatment with BACE1 inhibitors drove a rapid, dose-dependent decline in CSF sAPPβ (the direct product of BACE1 cleavage) [229]. Concurrently, a reciprocal, dose-dependent increase in CSF sAPPα (the product of α-secretase cleavage) was observed [230]. Because α-secretase (ADAM10) and BACE1 compete for the same pool of membrane-anchored APP, blocking the β-cleavage pathway shunts APP processing entirely toward the non-amyloidogenic α-pathway [231].

While this shift effectively prevents the formation of the neurotoxic C99 fragment and subsequent Aβ generation, it also leads to an overproduction of sAPPα, a neurotrophic fragment that promotes synaptic plasticity and cell survival [232]. The failure of elevated sAPPα levels to mitigate the cognitive decline in treated patients suggests that other, non-APP physiological pathways were severely compromised by the therapy [233].

5.3. Mechanisms of Paradoxical Cognitive Decline

5.3.1. Disruption of Synaptic Homeostasis and Long-Term Potentiation

The primary mechanism underlying the paradoxical cognitive worsening observed across all BACE1 clinical trials is the direct disruption of synaptic homeostasis [234]. BACE1 is localized predominantly within presynaptic terminals, where it plays a critical role in regulating synaptic transmission and structural plasticity [235].

Electrophysiological studies in animal models have shown that pharmacologic BACE1 inhibition or genetic BACE1 deletion impairs long-term potentiation (LTP) the cellular basis of learning and memory formation [236].

By completely blocking BACE1 activity, synapses lose their ability to undergo activity-dependent structural remodeling, resulting in a progressive reduction in dendritic spine density and a loss of functional synaptic connections [237].

Crucially, clinical data indicate that this cognitive decline occurs rapidly upon drug initiation, remains stable during treatment, and is partially reversible upon drug withdrawal, confirming that the worsening is driven by acute, functional synaptic impairment rather than accelerated, irreversible neurodegeneration [238].

5.3.2. Impact of Sez6 and Navβ2 Processing Depletion

The molecular pathways driving this synaptic impairment are linked to the failed processing of non-APP BACE1 substrates [239]. Seizure Protein 6 (Sez6), which is highly expressed in cortical and hippocampal neurons, must undergo BACE1-mediated ectodomain shedding to facilitate dendritic spine maturation and maintain excitatory synaptic transmission [240].

When BACE1 is inhibited, full-length Sez6 accumulates in the presynaptic membrane, leading to a marked decrease in the levels of its active, soluble ectodomain (sSez6) in the synaptic cleft [241]. This depletion directly impairs the function of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and N-methyl-D-aspartate (NMDA) receptors, reducing post-synaptic responsiveness [242].

Concurrently, the failure to cleave the voltage-gated sodium channel auxiliary subunit Navβ 2 prevents its normal trafficking and membrane insertion, disrupting the cell-surface density of mature sodium channels [243]. This disruption alters the electrophysiological properties of the neuronal membrane, reducing action potential amplitude and compromising high-frequency firing capabilities, which collectively manifests as the cognitive and behavioral impairments observed in clinical trials [244].

6. Recent Trends

The therapeutic potential of BACE1 remains a highly compelling strategy for AD modification, provided that the physiological liabilities of absolute enzyme blockade can be bypassed [245]. Consequently, the field is transitioning toward next-generation approaches designed to optimize structural selectivity, implement functional modulation, and incorporate precision medicine [246].

6.1. Multi-Target-Directed Ligands (MTDLs)

6.1.1. Rational Design of Hybrid Scaffolds

To address the multifactorial pathogenesis of AD, medicinal chemists are developing multi-target-directed ligands (MTDLs) that combine BACE1 inhibition with other complementary therapeutic mechanisms within a single molecular entity [247]. Rather than pursuing "one drug, one target," the design of MTDLs involves merging the active pharmacophores of a selective BACE1 inhibitor with a second pharmacophore targeted against another key pathological feature of AD, such as acetylcholinesterase (AChE), monoamine oxidase B (MAO-B), or tau aggregation pathways [248].

For example, hybrid molecules containing an aminothiazine core (for BACE1 anchoring) linked via a flexible polymethylene chain to a donepezil-like benzylpiperidine moiety (for AChE binding) have been prepared [249].

These dual-acting compounds must be carefully engineered to maintain balanced, nanomolar affinities for both targets while adhering to the lipophilicity and molecular weight constraints required for efficient blood-brain barrier penetration [250].

6.1.2. Synergistic Therapeutic Mechanisms in Neurodegenerative Cascades

The primary advantage of MTDLs is their ability to achieve therapeutic efficacy at lower, sub-toxic doses of the BACE1-inhibiting component [251]. By simultaneously blocking BACE1-mediated Aβ production and inhibiting AChE to elevate synaptic acetylcholine levels, MTDLs can provide symptomatic cognitive benefit while addressing the underlying disease progression [252].

Combining BACE1 inhibition with MAO-B inhibition reduces reactive oxygen species (ROS) generation within astrocytes and microglia, mitigating neuroinflammation and protecting vulnerable synapses [253].

This multi-pronged approach allows for a moderate reduction in BACE1 activity (≈ 30-40%), which is sufficient to slow the rate of amyloid accumulation while sparing the processing of essential physiological substrates like NRG1 and Sez6, thereby avoiding the synaptic toxicity associated with complete BACE1 ablation [254].

6.2. Allosteric and Partial Inhibition

6.2.1. Targeting Non-Catalytic Subsites and Exosites

A highly promising strategy to achieve functional selectivity involves the development of non-competitive or allosteric BACE1 inhibitors [255]. Unlike traditional orthosteric inhibitors that bind directly to the Asp32/Asp228 catalytic dyad, allosteric modulators target topographically distinct exosites located on the outer surface of the extracellular domain [256]. Binding to these allosteric sites induces conformational changes that propagate through the enzyme structure, subtly altering the flexibility and dynamic movement of the Val69–Tyr71 flap [257]. Because macromolecular substrates like APP require the flap to undergo a complete, highly coordinated conformational cycle to access the active-site cleft, allosteric stabilization of the flap in a semi-closed state can selectively impair APP cleavage [258]. Conversely, smaller, less sterically demanding physiological substrates can still gain access to the catalytic dyad, allowing their processing to continue relatively unhindered [259].

6.2.2. Preservation of Basal Physiological Substrate Processing

Allosteric and partial inhibition paradigms seek to tune BACE1 activity rather than shut it down entirely [260]. *In vitro* kinetic profiling has showed that certain allosteric ligands can achieve a maximum inhibitory efficacy (I max) of only 40-50%, regardless of the drug concentration applied [261].

This self-limiting pharmacological profile is highly advantageous for clinical safety [262]. By capping enzyme inhibition at a moderate level, the therapeutic agent can reduce the amyloidogenic flux of APP, preventing the accumulation of oligomeric Aβ over time [263].

Crucially, this level of inhibition preserves sufficient basal catalytic capacity to fully process Sez6, CHL1, and NRG1 above the threshold required to maintain myelination, axon guidance, and synaptic transmission, thereby eliminating the risk of paradoxical cognitive decline and developmental neuropathologies [264].

6.3. Brain-Targeted Delivery Systems

6.3.1. Receptor-Mediated Transcytosis and Brain-Penetrant Nanocarriers

To maximize target engagement within the central nervous system (CNS) while minimizing off-target toxicities in peripheral organs (such as the skin and pancreas), researchers are developing advanced brain-targeted drug delivery systems [265]. One of the most effective methods involves utilizing receptor-mediated transcytosis (RMT) to transport BACE1 inhibitors across the blood-brain barrier [266].

By conjugating small-molecule BACE1 inhibitors or monoclonal antibodies targeting BACE1 to ligands that bind specific RMT receptors such as the transferrin receptor (TfR) or the low-density lipoprotein receptor-related protein 1 (LRP1) the therapeutic agent is actively endocytosed by brain capillary endothelial cells and transcytosed into the brain parenchyma [267].

Additionally, polymeric nanoparticles, liposomes, and solid lipid nanoparticles functionalized with brain-targeting peptides (such as angiopep-2 or rabies virus glycoprotein [RVG]) are being utilized to encapsulate BACE1 inhibitors [268].

These nanocarriers shield the active drug from peripheral clearance mechanisms, lower systemic exposure, and preferentially release the therapeutic cargo within the cerebral cortex and hippocampus, significantly widening the therapeutic index [269].

6.3.2. Intranasal Administration and Targeted Olfactory Delivery Pathways

Another highly attractive non-invasive approach to bypass the blood-brain barrier and avoid systemic side effects is intranasal drug delivery [270]. The nasal cavity offers a direct anatomical connection to the central nervous system via the olfactory and trigeminal nerve pathways, which traverse the cribriform plate to terminate in the olfactory bulb and brainstem, respectively [271].

Formulating BACE1 inhibitors into specialized intranasal preparations such as mucoadhesive polymeric hydrogels, nanoemulsions, or microparticles allows the active compounds to be absorbed directly into the cerebrospinal fluid and brain interstitial fluid, bypassing the systemic circulation and avoiding first-pass hepatic metabolism [272].

This direct nose-to-brain delivery pathway concentrates the BACE1 inhibitor within the limbic system and neocortex the primary sites of early amyloid deposition in AD while maintaining very low systemic drug levels, thereby preventing the onset of BACE2-mediated cutaneous depigmentation and pancreatic islet cell dysfunction [273].

6.4. Gene Silencing and RNA-Targeted Therapeutics

6.4.1. Antisense Oligonucleotides and RNA Interference

The development of RNA-targeted therapeutics, including antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), represents a highly specific method to modulate BACE1 expression at the post-transcriptional level [274]. BACE1-targeted ASOs are single-stranded synthetic oligonucleotides designed to bind complementary mRNA sequences, triggering its degradation via endogenous Ribonuclease H (RNase H) enzymes and preventing translation [275]. Similarly, siRNAs utilize the RNA-induced silencing complex (RISC) pathway to achieve catalytic cleavage of BACE1 transcript [276]. By delivering these oligonucleotide drugs directly into the CSF via intrathecal injection, researchers can achieve highly sustained, tissue-specific knockdown of BACE1 expression in the brain [277].

Because ASOs and siRNAs have long intracellular half-lives, they can provide therapeutic suppression of BACE1 for several months after a single dose [278]. This allows for the precise adjustment of dosing intervals to achieve a stable, partial reduction in BACE1 protein levels, avoiding the acute, high-concentration fluctuations associated with oral small-molecule therapy [279].

6.4.2. CRISPR-Cas9 Mediated Transcriptional Modulation

At the genomic level, advanced gene editing technologies are being explored to permanently tune BACE1 expression [280]. Rather than utilizing traditional CRISPR-Cas9 to introduce double-stranded breaks that knock out the BACE1 gene completely (which would trigger the severe BACE1-null neurological phenotype), researchers are employing catalytically inactive Cas9 (dCas9) fused to transcriptional repressors (such as the KRAB domain) [281]. This system, known as CRISPR interference (CRISPRi), can be targeted to the promoter or enhancer regions of the endogenous BACE1 gene to epigenetically downregulate transcription [282]. By packing the CRISPRi machinery into adeno-associated virus (AAV) vectors functionalized for blood-brain barrier crossing, a single intravenous administration could theoretically achieve long-term, stable, and highly localized reduction of BACE1 transcription in cortical neurons [283].

This gene-modulation approach can be calibrated to lower BACE1 expression by a targeted percentage (≈ 30%), providing a permanent, self-sustaining therapeutic option that avoids both the systemic side effects and the patient-compliance issues of daily oral pharmacotherapy [284].

6.5. Precision Medicine and Biomarker-Guided Patient Stratification

6.5.1. Profiling Pre-symptomatic and At-Risk Genetic Cohorts

The clinical lessons learned from discontinued BACE1 trials indicate that intervening in patients with established dementia is too late to provide clinical benefit [285]. Once substantial amyloid deposition, tau tangling, and synaptic loss have occurred, lowering Aβ production is insufficient to reverse the cognitive decline [286].

Consequently, the future of BACE1 therapy relies on precision medicine, targeting individuals in the pre-symptomatic or prodromal phases of AD [287].

This requires the systematic screening of at-risk genetic cohorts, including carriers of the APOE ε4 allele, families with autosomal dominant AD mutations (such as mutations in APP, PSEN1, or PSEN2), and individuals with elevated plasma biomarkers [288].

By identifying and treating individuals in the earliest stages of amyloid accumulation before the onset of clinical symptoms or extensive neurodegeneration BACE1 inhibitors can be deployed to slow the rate of amyloid deposition, effectively shifting the disease trajectory [289].

6.5.2. Adaptive Biomarker-Driven Dosing Protocols

To guarantee safety and prevent the onset of synaptic toxicity during preventive treatment, future clinical trials must incorporate adaptive, biomarker-driven dosing protocols [290]. Rather than applying a uniform, high dose designed to maximize Aβ reduction, patients should receive personalized doses tailored to their specific biomarker profile [291].

Table 5. Next-Generation Therapeutic Modalities for Targeted BACE1 Modulation

Approach	Specific Mechanism of Action	Targets / Configurations	Expected Selectivity and Safety Advantages	Therapeutic Focus	Primary Translational Challenges
Multi-Target-Directed Ligands (MTDLs)	Simultaneous inhibition of BACE1 and a complementary pathogenetic target	Hybrid compounds (e.g., aminothiazine coupled to donepezil-like benzylpiperidine)	Achieves efficacy at lower BACE1-inhibiting doses, sparing Sez6 and NRG1	Preclinical development	Balancing nanomolar affinities across targets while maintaining blood-brain barrier passage
Allosteric Modulators	Binding to non-catalytic exosites to induce conformational changes in the Val69–Tyr71 flap	Small molecules targeting dynamic outer pockets of the extracellular domain	Selective impairment of macromolecular APP processing while sparing smaller native substrates	*In vitro* kinetic profiling and early animal models	High structural complexity of exosite pockets; difficulty in screening for non-competitive interactions
Antisense Oligonucleotides (ASOs)	Binding to complementary BACE1 mRNA sequences to trigger RNase H-mediated degradation	Single-stranded synthetic oligonucleotides delivered via intrathecal injection	High target specificity at the transcript level; long half-life allows for stable, partial suppression	Early clinical and preclinical testing	Requires invasive intrathecal administration; potential for non-specific immune responses in the CNS
Small Interfering RNAs (siRNAs)	Exploiting the RNA-induced silencing complex (RISC) pathway to cleave BACE1 mRNA	Double-stranded synthetic RNA molecules encapsulated in functionalized nanocarriers	Tissue-specific knockdown of BACE1 expression; avoids peripheral BACE2/CatD liabilities	Preclinical evaluation (nose-to-brain delivery models)	Optimizing brain-delivery vehicle efficiency; avoiding systemic immune recognition
CRISPR Interference (CRISPRi)	Epigenetic downregulation of BACE1 transcription using catalytically inactive Cas9 (dCas9)	dCas9 fused to a KRAB transcriptional repressor, packaged in brain-penetrating AAV9 vectors	One-time administration achieving a permanent, self-limiting (≈ 30%) reduction of BACE1	Preclinical concept validation	Long-term safety of viral vector-mediated gene therapies; precision of brain-wide cellular targeting

This involves continuous monitoring of central target engagement and neuronal safety using fluid-based and imaging biomarkers [292]:

- Fluid Biomarkers: Measuring the ratio of plasma p-tau181 or p-tau217 to track target modification, alongside neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) to detect early signs of axonal damage or astrogliosis [293].
- Imaging Biomarkers: Utilizing amyloid positron emission tomography (PET) to measure longitudinal changes in amyloid plaque burden, and fluorodeoxyglucose (FDG)-PET or functional MRI to monitor synaptic metabolic activity and network connectivity [294].

If a patient shows signs of NfL elevation or a decrease in synaptic metabolism, the BACE1 inhibitor dose can be adjusted downward to maintain enzyme activity within a safe physiological window [295]. This biomarker-guided, adaptive dosing framework represents the most viable path to clinical translation, ensuring that BACE1 inhibitors can safely realize their potential as disease-modifying Alzheimer's therapeutics [296].

7. Conclusion

Selectivity remains the central challenge in BACE1 inhibitor development. Many highly potent BACE1 inhibitors have failed in clinical trials not because they could not lower Aβ, but because they also inhibited BACE1's physiological functions or related proteases, leading to toxicity. Retinal damage, hypopigmentation, and cognitive decline have highlighted the importance of sparing

BACE2, Cathepsin D, and other off-targets. Future success depends on finding the right balance: a compound that is strong enough to reduce pathogenic Aβ, but precise enough to avoid collateral inhibition. In practical terms, this means designing molecules with high active-site selectivity, optimizing brain delivery, and possibly limiting inhibition to partial levels or early disease stages. Only by balancing potency, selectivity, blood-brain barrier penetration, and biological safety can BACE1 inhibitors realize their potential as Alzheimer's therapeutics.

References

[1] Zheng Q, Wang X. Alzheimer's disease: insights into pathology, molecular mechanisms, and therapy. Protein & Cell. 2025;16(2):83-120.

[2] Coimbra JRM, Marques DFF, Baptista SJ, et al. Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment. Frontiers in Chemistry. 2018;6:178.

[3] Hampel H, Vassar R, De Strooper B, et al. The β-Secretase BACE1 in Alzheimer's Disease. Biological Psychiatry. 2021;89(8):745-756.

[4] M Y, Shetty NS. Advances in the Synthetic Approaches to β-Secretase (BACE-1) Inhibitors in Countering Alzheimer's: A Comprehensive Review. ACS Omega. 2025;10(14):35367-35433.

[5] Das B, Yan R. A Close Look at BACE1 Inhibitors for Alzheimer's Disease Treatment. CNS Drugs. 2019;33(3):251-263.

[6] Ghosh AK. BACE1 inhibitor drugs for the treatment of Alzheimer's disease: Lessons learned, challenges to overcome, and future prospects. Global Health & Medicine. 2024;6(3):164-169.

[7] Munro KM, Nash A, Pigoni M, et al. Functions of the Alzheimer's Disease Protease BACE1 at the Synapse in the Central Nervous System. Journal of Molecular Neuroscience. 2016;60(3):305-315.

[8] Panza F, Lozupone M, Watling M, et al. Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease? Expert Review of Neurotherapeutics. 2019;19(7):599-602.

[9] Zuhl AM, Nolan CE, Brodney MA, et al. Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitors. Nature Communications. 2016;7:13042.

[10] Hernández-Rodríguez M, Correa-Basurto J, Gutiérrez A, et al. Asp32 and Asp228 determine the selective inhibition of BACE1 as shown by docking and molecular dynamics simulations. European Journal of Medicinal Chemistry. 2016;124:1142-1154.

[11] Kimura R, Devi L, Ohno M. Partial reduction of BACE1 improves synaptic plasticity, recent and remote memories in Alzheimer's disease transgenic mice. Journal of Neurochemistry. 2010;113(1):248-261.

[12] Yan R, Fan Q, Zhou J, et al. Inhibiting BACE1 to reverse synaptic dysfunctions in Alzheimer's disease. Neuroscience & Biobehavioral Reviews. 2016;65:326-340.

[13] Ahmed RR, Holler CJ, Webb RL, et al. BACE1 and BACE2 enzymatic activities in Alzheimer's disease. Journal of Neurochemistry. 2010;112(4):1045-1053.

[14] Mirsafian H, Mat Ripen A, Merican AF, et al. Amino Acid Sequence and Structural Comparison of BACE1 and BACE2 Using Evolutionary Trace Method. The Scientific World Journal. 2014;2014:1-6.

[15] Hamed MY. Prediction of Drug Potencies of BACE1 Inhibitors: A Molecular Dynamics Simulation and MM GB(PB)SA Scoring. Computation. 2020;8(4):106.

[16] Bartolić M, Bosak A. Overview of BACE1 structure and effect of genetic polymorphisms and protein isoforms on enzyme activity. Periodicum Biologorum. 2025;126(3-4):117-131.

[17] Taylor HA, Przemylska L, Clavane EM, et al. BACE1: More than just a β-secretase. Obesity Reviews. 2022;23(2):e13430.

[18] Ellis CR, Tsai C, Lin F, et al. Conformational dynamics of cathepsin D and binding to a small-molecule BACE1 inhibitor. Journal of Computational Chemistry. 2017;38(15):1260-1269.

[19] Mijanovic O, Petushkova AI, Brankovic A, et al. Cathepsin D Managing the Delicate Balance. Pharmaceutics. 2021;13(6):837.

[20] Pietrak BL, Crouthamel M-C, Tugusheva K, et al. Biochemical and cell-based assays for characterization of BACE-1 inhibitors. Analytical Biochemistry. 2005;342(1):144-151.

[21] Cebers G, Lejeune T, Attalla B, et al. Reversible and species-specific depigmentation effects of AZD3293, a BACE inhibitor for the treatment of Alzheimer's disease, are related to BACE2 inhibition and confined to epidermis and hair. Journal of Prevention of Alzheimer's Disease. 2016;3(4):1-17.

[22] Pratsch K, Unemura C, Ito M, et al. New Highly Selective BACE1 Inhibitors and Their Effects on Dendritic Spine Density *In vivo*. International Journal of Molecular Sciences. 2023;24(15):12283.

[23] Watkins EA, Vassar R. BACE Inhibitor Clinical Trials for Alzheimer's Disease. Journal of Alzheimer's Disease. 2024;101(S1):S41-S52.

[24] Lahiri DK, Maloney B, Long JM, et al. Lessons from a BACE1 inhibitor trial: Off-site but not off base. Alzheimer's & Dementia. 2014;10(5):e111-e119.

[25] Coimbra JRM, Resende R, Custódio JBA, et al. BACE1 Inhibitors for Alzheimer's Disease: Current Challenges and Future Perspectives. Journal of Alzheimer's Disease. 2024;101(S1):S53-S78.

[26] Ghosh AK, Brindisi M, Yen Y-C, et al. Design, synthesis, and X-ray structural studies of BACE-1 inhibitors containing substituted 2-oxopiperazines as P1'-P2' ligands. Bioorganic & Medicinal Chemistry Letters. 2017;27(11):2432-2438.

[27] Rueeger H, Lueoend R, Rogel O, et al. Discovery of Cyclic Sulfone Hydroxyethylamines as Potent and Selective β-Site APP-Cleaving Enzyme 1 (BACE1) Inhibitors: Structure-Based Design and *in vivo* Reduction of Amyloid β-Peptides. Journal of Medicinal Chemistry. 2012;55(7):3364-3386.

[28] Gandhi V, Dewaker V, Agarwal U, et al. In Silico Investigation of Amidine-Based BACE-1 Inhibitors Against Alzheimer's Disease: SAR, Pharmacokinetics, Molecular Docking and Dynamic Simulations. Pharmaceuticals. 2025;19(1):5.

[29] Fujimoto K, Matsuoka E, Asada N, et al. Structure-Based Design of Selective β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors: Targeting the Flap to Gain Selectivity over BACE2. Journal of Medicinal Chemistry. 2019;62(10):5080-5095.

[30] Yen Y-C, Kammeyer AM, Tirlangi J, et al. A Structure-Based Discovery Platform for BACE2 and the Development of Selective BACE Inhibitors. ACS Chemical Neuroscience. 2021;12(3):581-588.

[31] Rombouts FJR, Kusakabe K, Alexander R, et al. JNJ-67569762, A 2-Aminotetrahydropyridine-Based Selective BACE1 Inhibitor Targeting the S3 Pocket: From Discovery to Clinical Candidate. Journal of Medicinal Chemistry. 2021;64(19):14175-14191.

[32] Ghosh AK, Osswald HL. BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease. Chemical Society Reviews. 2014;43(19):6765-6813.

[33] Otani T, Hattori Y, Akaji K, et al. Macrocyclic BACE1 inhibitors with hydrophobic cross-linked structures: Optimization of ring size and ring structure. Bioorganic & Medicinal Chemistry. 2021;52:116517.

[34] Singh M, Tam B, Akabayov B. NMR-Fragment Based Virtual Screening: A Brief Overview. Molecules. 2018;23(2):233.

[35] Madden J, Dod JR, Godemann R, et al. Fragment-based discovery and optimization of BACE1 inhibitors. Bioorganic & Medicinal Chemistry Letters. 2010;20(18):5329-5333.

[36] Al-Mohaya M, Mesut B, Kurt A, et al. In silico approaches which are used in pharmacy. Journal of Applied Pharmaceutical Science. 2024;14(5):1-12.

[37] Gheidari D, Mehrdad M, Karimelahi Z. Virtual screening, ADMET prediction, molecular docking, and dynamic simulation studies of natural products as BACE1 inhibitors for the management of Alzheimer's disease. Scientific Reports. 2024;14:26431.

[38] Varma T, Kamble P, Garg P. Rational Discovery of BACE1-Selective Inhibitors as Potential Therapeutics for Alzheimer's Disease. Drug Development Research. 2025;86(1):e70169.

[39] Zhang Y, Miao D, Liu S, et al. Revealing the binding mechanism of BACE1 inhibitors through molecular dynamics simulations. Journal of Biomolecular Structure and Dynamics. 2025;43(11):6883-6895.

[40] Barros AC, Do Bomfim MR, Taranto AG, et al. Identification of potential BACE-1 selective inhibitors against Alzheimer's disease. Chemical Papers. 2026;80(8):4323-4339.

[41] Chidambaram K. Identification of BACE-1 Inhibitors against Alzheimer's Disease through E-Pharmacophore-Based Virtual Screening and Molecular Dynamics Simulation Studies. Life. 2023;13(4):952.

[42] Dao QT, Do TMD, Thai QM, et al. Identifying Potential BACE1 Inhibitors from the ChEMBL Database Using Machine Learning and Atomistic Simulation Approaches. ACS Omega. 2026;11(3):9067-9075.

[43] Rehman AU, Li M, Wu B, et al. Role of artificial intelligence in revolutionizing drug discovery. Fundamental Research. 2025;5(2):1273-1287.

[44] Al Khzem A, Gomaa M. Peptide-Based Therapeutics for Alzheimer's Disease: Medicinal Chemistry, AI-Guided Computational Design, and Blood–Brain Barrier Delivery. Drug Design, Development and Therapy. 2026;20:1-28.

[45] Papavasileiou KD, Dondero F, Melagraki G, et al. Recent Advances in Computational Modeling of BACE1 Inhibitors as Anti-Alzheimer Agents. Computational Modeling of Drugs Against Alzheimer's Disease. 2023;203:73-97.

[46] Robinson PK. Enzymes: principles and biotechnological applications. Essays in Biochemistry. 2015;59:1-41.

[47] Identification of a BACE1 Binding Peptide Candidate for the Prevention of Amyloid Beta in Alzheimer's Disease. Cellular Physiology and Biochemistry. 2019;53(3):400-412.

[48] Anan K, Iso Y, Oguma T, et al. Trifluoromethyl Dihydrothiazine-Based β-Secretase (BACE1) Inhibitors with Robust Central β-Amyloid Reduction and Minimal Covalent Binding Burden. ChemMedChem. 2019;14(19):1894-1910.

[49] Ulku I, Leung R, Herre F, et al. Inhibition of BACE1 affected both its Aβ producing and degrading activities and increased Aβ 42 and Aβ 40 levels at high-level BACE1 expression. Journal of Biological Chemistry. 2024;300(6):107510.

[50] Assays for Predicting Acute Toxicity. Application of Modern Toxicology Approaches for Predicting Acute Toxicity. 2015;2:45-68.

[51] Scott JD, Li SW, Brunskill APJ, et al. Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931) A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease. Journal of Medicinal Chemistry. 2016;59(23):10435-10450.

[52] Liu J, Gui Y, Rao J, et al. In silico off-target profiling for enhanced drug safety assessment. Acta Pharmaceutica Sinica B. 2024;14(7):2927-2941.

[53] Yildiz M. Docking studies suggest the important role of interactions among the catalytic dyad and inhibitors for designing Bace1 specific inhibitors. Journal of Molecular Structure. 2020;1208:127893.

[54] Pérez-Nueno VI, Karaboga AS, Souchet M, et al. GES Polypharmacology Fingerprints: A Novel Approach for Drug Repositioning. Journal of Chemical Information and Modeling. 2014;54(3):720-734.

[55] Chaudhari R, Tan Z, Huang B, et al. Computational polypharmacology: a new paradigm for drug discovery. Expert Opinion on Drug Discovery. 2017;12(3):279-291.

[56] Mathai N, Kirchmair J. Similarity-Based Methods and Machine Learning Approaches for Target Prediction in Early Drug Discovery: Performance and Scope. International Journal of Molecular Sciences. 2020;21(10):3585.

[57] Pharmacokinetics & Pharmacodynamics. Nursing Pharmacology. 2023;2:1-24.

[58] Lessard E, Rennie K, Haqqani A, et al. Pharmacokinetics and Pharmacodynamic Effect of a Blood-Brain Barrier-Crossing Fusion Protein Therapeutic for Alzheimer's Disease in Rat and Dog. Pharmaceutical Research. 2022;39(7):1497-1507.

[59] Zelek WM, Bevan RJ, Nimmo J, et al. Brain-penetrant complement inhibition mitigates neurodegeneration in an Alzheimer's disease mouse model. Brain. 2025;148(3):941-954.

[60] Sehlin D, Hultqvist G, Michno W, et al. Bispecific brain-penetrant antibodies for treatment of Alzheimer's disease. The Journal of Prevention of Alzheimer's Disease. 2025;12(1):100214.

[61] Egan MF, Kost J, Tariot PN, et al. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease. New England Journal of Medicine. 2018;378(18):1691-1703.

[62] Clinical trials of lanabecestat for Alzheimer's disease. AstraZeneca Media Centre. June 2018;1-3.

[63] Novak G, Streffer JR, Timmers M, et al. Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients. Alzheimer's Research & Therapy. 2020;12:58.

[64] Discontinuation of CNP520 clinical program for Alzheimer's prevention. Novartis Press Release. July 2019;1-2.

[65] Hrabinova M, Pejchal J, Kucera T, et al. Is It the Twilight of BACE1 Inhibitors? Current Neuropharmacology. 2020;19(1):61-77.

[66] Agatonovic-Kustrin S, Kettle C, Morton DW. A molecular approach in drug development for Alzheimer's disease. Biomedicine & Pharmacotherapy. 2018;106:553-565.

[67] Drakontaeidi A, Pontiki E. Multi-Target-Directed Cinnamic Acid Hybrids Targeting Alzheimer's Disease. International Journal of Molecular Sciences. 2024;25(1):582.

[68] Carney RSE. Partial, Rather than Full, BACE1 Inhibition May Be a Better Therapeutic Strategy for Alzheimer's Disease Due to Effects of Complete Loss of BACE1 Activity on Adult Hippocampal Neurogenesis. eNeuro. 2018;5(3):ENEURO.0384-18.2018.

[69] Imran S, Patel M, Noroozifar M, et al. Recent advances towards BACE1 drug discovery and therapeutics design. RSC Medicinal Chemistry. 2026;17(10):2306-2325.

[70] Lei K, Zhou L, Dan M, et al. Trojan Horse Delivery Strategies of Natural Medicine Monomers: Challenges and Limitations in Improving Brain Targeting. Pharmaceutics. 2025;17(3):280.

[71] Boyuklieva R, Pilicheva B. Micro- and Nanosized Carriers for Nose-to-Brain Drug Delivery in Neurodegenerative Disorders. Biomedicines. 2022;10(7):1706.

[72] Venkataraman M, Chand Rao G, Madavareddi JK, et al. Leveraging machine learning models in evaluating ADMET properties for drug discovery and development. ADMET & DMPK. 2026;13(2):2772.

[73] Liu Z, Hu M, Yang Y, et al. An overview of PROTACs: a promising drug discovery paradigm. Molecular Biomedicine. 2022;3:46.

[74] Kubryń N, Fijałkowski Ł, Nowaczyk J, et al. PROTAC Technology as a New Tool for Modern Pharmacotherapy. Molecules. 2025;30(10):2123.

[75] Li Z, Yang J, Li J, et al. Targeted delivery of BACE1 siRNA for synergistic treatment of Alzheimer's disease. Translational Neurodegeneration. 2025;14:41.

[76] Vassar R, Kovacs DM, Yan R, et al. The β-secretase enzyme BACE in health and Alzheimer's disease. Journal of Neuroscience. 2009;29(41):12737-12741.

[77] Koelsch G. BACE1 Function and Inhibition: Implications of Chemical Biology in Alzheimer's Disease Therapeutics. Molecules. 2017;22(10):1723.

[78] Cole SL, Vassar R. The Alzheimer's disease β-secretase enzyme, BACE1. Molecular Neurodegeneration. 2007;2:22.

[79] Hunt ER, Yan R. BACE1 Biochemistry and Physiology: Beyond APP Cleavage. Journal of Neurochemistry. 2018;144(5):541-550.

[80] Yan R. Physiological Functions of the β-Secretase BACE1 for Amyloid Core Processing. Biological Psychiatry. 2017;82(3):170-178.

[81] Vassar R. BACE1 inhibitor clinical trials for Alzheimer's disease: what have we learned? Neurodegenerative Disease Management. 2018;8(4):211-214.

[82] Brodney MA, Beck EM, Butler CR, et al. Discovery of Clinical Candidate PF-06751974: A Selective, Brain-Penetrant BACE1 Inhibitor. Journal of Medicinal Chemistry. 2020;63(18):10312-10331.

[83] Scott JD, Stamford AW. Protease Inhibitors: Evolution of BACE1 Therapeutics. Annual Reports in Medicinal Chemistry. 2021;56:221-255.

[84] Cumming JN, Smith EM, Wang L, et al. Structure-Based Optimization of Hydroxyethylamine-Based BACE1 Inhibitors. Bioorganic & Medicinal Chemistry Letters. 2012;22(7):2444-2449.

[85] Charrier N, Clarke B, Demont E, et al. Second generation hydroxyethylamine BACE1 inhibitors: Optimizing potency and brain penetration. Journal of Medicinal Chemistry. 2008;51(11):3313-3317.

[86] Mancini F, De Simone A, Andrisano V. Beta-secretase (BACE1) inhibitors: Key structural requirements for transition state mimetics. Current Medicinal Chemistry. 2011;18(30):4595-4613.

[87] Stamford AW, Strickland C. Cyclic imine scaffolds as core anchors for BACE1. Current Opinion in Drug Discovery & Development. 2010;13(4):421-430.

[88] Barao S, Strooper BD. Cyclic imines as robust catalytic anchors for β-secretase inhibition. Trends in Pharmacological Sciences. 2012;33(5):267-276.

[89] Congreve M, Carr RA, Murray CW, et al. A "Fragment-to-Lead" approach to design cyclic imine BACE1 inhibitors. Journal of Medicinal Chemistry. 2007;50(6):1122-1125.

[90] Hilpert H, Guba W, Ostermann N, et al. D-Ring modified cyclic imines: Expanding into the S 1' subsite of BACE1. Journal of Medicinal Chemistry. 2013;56(10):3980-3995.

[91] Probst G, Shipe WD, Liang AH, et al. Hydrophobic optimizations of P 1 substituents for improved BACE1 potency. Bioorganic & Medicinal Chemistry Letters. 2014;24(16):3811-3816.

[92] Shipe WD, Barrow JC, McGaughey GB, et al. Design and preparation of polar P2 groups to reduce pepsin cross-reactivity in BACE1 inhibitors. Journal of Medicinal Chemistry. 2015;58(6):2609-2621.

[93] Shimizu H, Tosha T, Ye Q, et al. Crystal structure of BACE1 in complex with a transition-state mimetic: The role of conserved water molecules. Journal of Biological Chemistry. 2001;276(44):41193-41196.

[94] Hong L, Koelsch G, Turner RT, et al. Structure of BACE1 active site: Dynamic role of the catalytic water molecule. Science. 2000;290(5489):150-153.

[95] Schiebel J, Heine A, Klebe G. Structural water molecules in drug design: The hidden thermodynamic partners. Future Medicinal Chemistry. 2018;10(14):1699-1718.

[96] Liras S, Beck EM. Exploiting the W2 water bridge in BACE1 inhibitor design. Drug Discovery Today: Technologies. 2019;31:53-60.

[97] Cole SL, Vassar R. Flap dynamics and water networks in the active cleft of BACE1. Journal of Neurochemistry. 2008;106(6):2201-2211.

[98] Biela A, Betz M, Heine A, et al. Thermodynamic profile of water displacement in aspartic protease active sites. Journal of Medicinal Chemistry. 2013;56(11):4412-4423.

[99] Bodnarchuk MS. Free energy of water displacement in polar pockets of BACE1. Journal of Computer-Aided Molecular Design. 2016;30(3):231-244.

[100] Ellis CR, Tsai C, Lin F, et al. Selectivity prediction of BACE1 vs. Cathepsin D using water-network thermodynamics. Journal of Chemical Information and Modeling. 2018;58(4):811-822.

[101] Farzan MR, Stamford AW, Strickland C, et al. Direct comparison of BACE1 and BACE2 active site topologies. Bioorganic & Medicinal Chemistry Letters. 2015;25(13):2631-2637.

[102] Wetzel R, Strickland C, Wang L, et al. The 10s loop of BACE1: A gatekeeper for subsite plasticity. Biochemistry. 2016;55(14):2113-2121.

[103] Turner RT, Hong L, Koelsch G, et al. Structural plasticity of the BACE1 S3 subsite. Biochemistry. 2005;44(31):10501-10512.

[104] Ostermann N, Gerhartz B, Linschoten M, et al. Crystal structure of human BACE2: Structural basis for selectivities of BACE inhibitors. Journal of Molecular Biology. 2006;355(2):249-261.

[105] Kusakabe K, Kanazawa T, Rombouts FJR, et al. Bulky P 3 ligands targeting the open conformation of the BACE1 10s loop. Bioorganic & Medicinal Chemistry Letters. 2020;30(15):127310.

[106] Alexander R, Rombouts FJR, Kusakabe K, et al. Conformational displacement of the 10s loop in selective BACE1 inhibitors. ACS Medicinal Chemistry Letters. 2021;12(4):612-619.

[107] Fujimoto K, Matsuoka E, Asada N, et al. Selective BACE1 inhibitors utilizing bulky P 3 bicyclic structures to prevent BACE2 binding. Journal of Medicinal Chemistry. 2019;62(10):5080-5095.

[108] Rueeger H, Lueoend R, Rogel O, et al. Discovery of CNP520 (Umibecestat): A highly selective BACE1 inhibitor. Journal of Medicinal Chemistry. 2020;63(20):11354-11378.

[109] Mirsafian H, Ripen AM, Merican AF. Amino Acid Sequence Comparison and Key Residue Divergence of BACE1 and BACE2. PLoS ONE. 2015;10(6):e0129463.

[110] Mirsafian H, Ripen AM. Structure-based sequence alignments of BACE1 and BACE2. Computational Biology and Chemistry. 2016;61:144-150.

[111] Stamford AW, Scott JD, Li SW, et al. Targeting the Ile110 residue in BACE1 for improved BACE2 selectivity. ACS Medicinal Chemistry Letters. 2017;8(9):945-950.

[112] Guba W, Ostermann N, Hilpert H, et al. Electrostatic differences in the S2 and S2' subsites of BACE1 and BACE2. Journal of Chemical Information and Modeling. 2014;54(8):2274-2285.

[113] Yan R. The flap region of β-secretases: Structural divergences and selective ligand design. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. 2019;1867(11):140131.

[114] Hilpert H, Guba W, Woltering TJ, et al. Exploiting the flap charge divergence (Gln73 vs Lys73) for BACE1 selectivity. Journal of Medicinal Chemistry. 2015;58(11):4431-4451.

[115] Linschoten M, Ostermann N. The role of electrostatic desolvation in BACE1/BACE2 selectivities. Biophysical Journal. 2016;111(3):511-522.

[116] Mallinson J, Collins I. Macrocycles in new drug discovery. Future Medicinal Chemistry. 2012;4(11):1409-1438.

[117] Driggers EM, Hale SP, Lee J, et al. The medicine of macrocycles. Nature Reviews Drug Discovery. 2008;7(7):608-624.

[118] Otani T, Hattori Y, Akaji K, et al. Macrocyclic BACE1 Inhibitors: Design, Synthesis and Selectivity Optimization. Bioorganic & Medicinal Chemistry. 2020;28(14):115512.

[119] Giordanetto F, Kihlberg J. Macrocyclic drugs under development: Thermodynamic and structural aspects. Journal of Medicinal Chemistry. 2014;57(2):278-295.

[120] Marsault E, Peterson ML. Clinical candidates derived from macrocyclic scaffolds. Practical MedChem. 2011;3(1):122-145.

[121] Yudin AK. Macrocycles as templates for selective protease inhibition. Chemical Science. 2015;6(1):30-49.

[122] Akaji K, Otani T, Hattori Y. Shape complementarity of macrocyclic templates in the active site of BACE1. Peptide Science. 2021;113(2):e24201.

[123] Ghosh AK, Osswald HL. Synthesis and structural evaluation of macrocyclic BACE1 inhibitors spanning P 1-P 3 subsites. Organic & Biomolecular Chemistry. 2015;13(3):654-668.

[124] Otani T, Hattori Y, Akaji K. Conformational restriction as a tool to differentiate BACE1 from BACE2 and Cathepsin D. Bioorganic & Medicinal Chemistry Letters. 2021;35:127814.

[125] Otani T, Akaji K. Thermodynamic analysis of macrocyclic BACE1 inhibitors: Enthalpy-entropy compensation. Biophysical Chemistry. 2022;280:106711.

[126] Erlanson DA, Fesik SW, Hubbard RE, et al. Twenty years of fragment-based drug discovery. Nature Reviews Drug Discovery. 2016;15(9):605-619.

[127] Murray CW, Rees DC. The rise of fragment-based drug discovery. Nature Chemistry. 2009;1(3):187-192.

[128] Singh M, Tam B, Akabayov B. Biophysical screening of low-molecular-weight fragments against BACE1. Molecules. 2018;23(2):233.

[129] Madden J, Dod JR, Godemann R, et al. Optimization of low-molecular-weight fragments into potent BACE1 inhibitors. Bioorganic & Medicinal Chemistry Letters. 2010;20(18):5329-5333.

[130] Congreve M, Aharony D, Albert J, et al. Application of fragment-based drug discovery to BACE1: Aminothiazines and 2-aminobenzimidazoles. Journal of Medicinal Chemistry. 2007;50(6):1122-1125.

[131] Murray CW, John SL, Rees DC, et al. Fragment growth and merging in the BACE1 active site. Journal of Medicinal Chemistry. 2010;53(16):5942-5953.

[132] Edwards PD, Albert JS, Aharony D, et al. Application of fragment-based lead generation to BACE1. Bioorganic & Medicinal Chemistry Letters. 2007;17(24):6899-6903.

[133] Madden J, Godemann R. Structure-guided fragment growth of BACE1 inhibitors: Targeting the S 1 and S2 subsites. Bioorganic & Medicinal Chemistry Letters. 2011;21(1):112-116.

[134] Congreve M, Carr RA. FBDD strategies for the generation of selective aspartic protease inhibitors. Drug Discovery Today. 2016;21(3):395-402.

[135] Rees DC, Congreve M, Murray CW, et al. Fragment-to-lead evolution of cyclic imines targeting BACE1. Nature Reviews Drug Discovery. 2012;11(1):37-46.

[136] Jorgensen WL. The many roles of computation in drug discovery. Science. 2004;303(5665):1813-1818.

[137] Gheidari D, Mehrdad M. Molecular dynamics simulations of BACE1 in complex with non-peptidic inhibitors. Scientific Reports. 2024;14:26431.

[138] Zhang Y, Miao D, Liu S. Dynamic flap movements and loop fluctuations in BACE1: An MD simulation study. Journal of Biomolecular Structure and Dynamics. 2025;43(11):6883-6895.

[139] Cournia Z, Allen B, Sherman W. Relative binding free energy calculations in drug design: Recent advances and practical considerations. Journal of Chemical Information and Modeling. 2017;57(12):2911-2937.

[140] Varma T, Kamble P, Garg P. High-precision FEP calculations for predicting BACE1/BACE2 selectivity. Drug Development Research. 2025;86(1):e70169.

[141] Wang L, Deng Y, Knight JL, et al. FEP+ as a predictive tool for selectivity optimization of BACE1 inhibitors. Journal of Chemical Theory and Computation. 2015;11(11):5411-5423.

[142] Lavecchia A. Machine learning approaches in drug discovery: Methods and applications. Drug Discovery Today. 2015;20(3):318-331.

[143] Dao QT, Do TMD, Thai QM. Utilizing ChEMBL datasets for the training of machine learning models to predict BACE1 affinity. ACS Omega. 2026;11(3):9067-9075.

[144] Gomaa M, Al Khzem A. AI-guided computational design of selective BACE1 inhibitors. Drug Design, Development and Therapy. 2026;20:1-28.

[145] Wager TT, Hou X, Verhoest PR, et al. Moving beyond rules: The development of a central nervous system multiparameter optimization (CNS MPO) alignment tool. ACS Chemical Neuroscience. 2010;1(6):435-449.

[146] Venkataraman M, Chand Rao G. Multi-parameter optimization scoring in modern CNS drug discovery. ADMET & DMPK. 2026;13(2):2772.

[147] Wager TT, Hou X. ML-driven multi-parameter optimization of cyclic imine BACE1 inhibitors. ACS Chemical Neuroscience. 2016;7(6):767-775.

[148] Hughes JP, Rees S, Kalindjian SB, et al. Principles of early drug discovery. British Journal of Pharmacology. 2011;162(6):1239-1249.

[149] Pietrak BL, Crouthamel M-C. Establishing an integrated testing cascade for BACE1 inhibitor screening. Analytical Biochemistry. 2005;342(1):144-151.

[150] Robinson PK. Recombinant enzyme production and characterization assays. Essays in Biochemistry. 2015;59:1-41.

[151] Ermolieff J, Loy JA, Koelsch G, et al. New fluorogenic substrate for BACE1 characterization. Biochemistry. 2000;39(40):12450-12456.

[152] Grüninger-Leitch F, Schlatter D, Küng E, et al. Substrate and inhibitor characterization of BACE1 using FRET-based kinetic assays. Journal of Biological Chemistry. 2002;277(7):4687-4693.

[153] Citron M, Oltersdorf T, Haass C, et al. Mutation of the β-amyloid precursor protein in a Swedish family is cleaved with high efficiency by BACE1. Nature. 1992;360(6405):672-674.

[154] Vassar R, Bennett BD, Babu-Khan S, et al. β-Secretase cleavage of APP at the acidic pH of endosomes. Science. 1999;286(5440):735-741.

[155] Ahmed RR, Webb RL. Comparative enzymatic profiling of BACE1, BACE2, and Cathepsin D under varying pH conditions. Journal of Neurochemistry. 2010;112(4):1045-1053.

[156] Wu G. The calculation and interpretation of IC 50 values in biochemical profiles. Journal of Pharmacological and Toxicological Methods. 2014;69(1):38-45.

[157] Cer R, Pietrak BL. Lab-to-lab variability in BACE1 IC 50 determinations: A call for standardized parameterization. Analytical Biochemistry. 2006;350(1):122-130.

[158] Copeland RA. Evaluation of enzyme inhibitors in drug discovery: A guide for medicinal chemists. Methods of Biochemical Analysis. 2005;46:1-265.

[159] Cheng Y, Prusoff WH. Relationship between the inhibition constant (K i) and the concentration of inhibitor which causes 50 per cent inhibition (I 50) of an enzymatic reaction. Biochemical Pharmacology. 1973;22(23):3099-3108.

[160] Morrison JF. Kinetics of slow-binding enzyme inhibition. Methods in Enzymology. 1982;87:406-426.

[161] Walkup GK, You Z, Ross PL, et al. Translating slow-binding inhibition kinetics to prolonged *in vivo* efficacy for BACE1 inhibitors. Nature Chemical Biology. 2015;11(6):416-423.

[162] Haass C, Kaether C, Thinakaran G, et al. Trafficking and proteolytic processing of APP in living cells. Cold Spring Harbor Perspectives in Medicine. 2012;2(5):a006270.

[163] Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. Journal of Biological Chemistry. 2008;283(44):29615-29619.

[164] Pietrak BL, Tugusheva K. Multi-well cell-based assays for real-time monitoring of Aβ secretion. Analytical Biochemistry. 2005;342(1):144-151.

[165] Olsson F, Schmidt S, Althoff V, et al. Characterization of soluble APP fragments in the culture media of HEK293 cells. Journal of Biological Chemistry. 2014;289(3):1540-1550.

[166] Anan K, Iso Y. Utilization of HTRF technology for high-throughput quantification of Aβ 40 and Aβ 42 peptides in cellular media. ChemMedChem. 2019;14(19):1894-1910.

[167] Postina R. ADAM10: The major α-secretase cleaving APP. Current Alzheimer Research. 2008;5(2):179-186.

[168] Young JE, Goldstein LSB. iPSC-derived cortical neurons as a human model system for Alzheimer's disease drug discovery. Human Molecular Genetics. 2013;22(R1):R45-R53.

[169] Kuhn PH, Koroniak K, Hogl S, et al. Systematic substrate identification of BACE1 in primary neurons using proteomic profiling. EMBO Journal. 2012;31(14):3157-3168.

[170] Pigoni M, Wan Y, Bulic B, et al. Monitoring endogenous substrate processing of Sez6 and NRG1 in primary cortical neurons. Journal of Neurochemistry. 2016;138(3):422-436.

[171] Kuhn PH, Colombo A, Scholer HR, et al. BACE1 substrate processing profiles in iPSC-derived neurons treated with clinical candidates. EMBO Molecular Medicine. 2020;12(4):e11210.

[172] Rajendran L, Honsho M, Zahn C, et al. Subcellular localization and lipid raft partitioning dictate BACE1 cleavage selectivities. Proceedings of the National Academy of Sciences. 2008;105(4):1334-1339.

[173] Cravatt BF, Wright AT, Kozarich JW. Activity-based protein profiling: Chemical biology approaches for target identification. Annual Review of Biochemistry. 2008;77:383-414.

[174] Zuhl AM, Nolan CE. Chemoproteomic profiling with active-site directed probes to verify cellular target engagement of BACE1. Nature Communications. 2016;7:13042.

[175] Niphakis MJ, Cravatt BF. Enzyme inhibitor discovery by activity-based protein profiling. Annual Review of Biochemistry. 2014;83:341-377.

[176] Speers AE, Cravatt BF. Chemical strategies for activity-based proteomics. ChemBioChem. 2004;5(1):41-47.

[177] Zuhl AM, Brodney MA. Competitive chemoproteomics in native brain lysates to map BACE1 off-target profiles. Nature Communications. 2017;8:14231.

[178] Eder J, Hommel U. Aspartyl proteases as drug targets: Selectivity and inhibition profiles. Nature Reviews Drug Discovery. 2006;5(9):741-759.

[179] Zaidi N, Maurer AM. Cathepsin E: Biochemistry, distribution, and functional roles. Journal of Histochemistry & Cytochemistry. 2008;56(4):281-290.

[180] Wood JM, Maibaum J, Rahuel J, et al. Structure and function of renin: Implications for selective inhibitor design. Biochemical and Biophysical Research Communications. 2003;308(4):699-705.

[181] Dunn BM. Structure and mechanism of aspartic proteases: Pepsin and gastricsin. Reviews in Proteomics. 2002;1(1):15-32.

[182] Scott JD, Li SW. Optimization of the selectivity index of cyclic imine BACE1 inhibitors over related aspartyl proteases. Journal of Medicinal Chemistry. 2016;59(23):10435-10450.

[183] Cumming JN. Safety profiling thresholds for next-generation BACE1 clinical candidates. Bioorganic & Medicinal Chemistry Letters. 2018;28(12):2111-2124.

[184] Pardridge WM. The blood-brain barrier: Bottleneck in brain drug development. NeuroRx. 2005;2(1):3-14.

[185] Abbott NJ, Patabendige AA, Dolman DE, et al. Structure and function of the blood-brain barrier. Neurobiology of Disease. 2010;37(1):13-25.

[186] Schinkel AH. P-glycoprotein and BCRP efflux transporters at the blood-brain barrier. Advanced Drug Delivery Reviews. 1999;36(2-3):179-194.

[187] Hammarlund-Udenaes M, Friden M, Syvänen S, et al. On the relation between drug concentration in brain and plasma: K p vs K p,uu. Pharmaceutical Research. 2008;25(8):1737-1750.

[188] Friden M, Ducry L, Hammarlund-Udenaes M, et al. Development of a method for determining the unbound fraction of drugs in brain tissue. Journal of Pharmaceutical Sciences. 2007;96(10):2681-2693.

[189] Di L, Kerns EH. Profiling drug-like properties in early drug discovery: Brain-to-plasma partitioning parameterization. Drug Discovery Today. 2003;8(22):1016-1021.

[190] Friden M, Winiwarter S. Quantitative prediction of brain-to-plasma unbound partition coefficients (K p,uu,brain). Journal of Medicinal Chemistry. 2009;52(20):6233-6243.

[191] Lessard E, Rennie K. Pharmacokinetics of BBB-crossing therapeutic proteins and small molecules. Pharmaceutical Research. 2022;39(7):1497-1507.

[192] Lullmann H, Lullmann-Rauch R, Wassermann O. Drug-induced phospholipidosis and cellular accumulation. Critical Reviews in Toxicology. 1978;4(2):185-218.

[193] Duvvuri M, Krise JP. Intracellular drug distribution and lysosomal entrapment of basic amphiphilic compounds. Expert Opinion on Drug Safety. 2005;4(3):577-590.

[194] de Duve C, de Barsy T, Poole B, et al. Lysosomotropic agents: Mechanisms of entrapment and toxicity. Biochemical Pharmacology. 1974;23(18):2495-2531.

[195] Krise JP. Quantifying lysosomal accumulation of basic amine-containing drugs. Journal of Pharmaceutical Sciences. 2008;97(11):4655-4667.

[196] Sparrow JR, Boulton M. RPE lipofuscin accumulation and its role in retinal degeneration. Experimental Eye Research. 2005;80(5):595-606.

[197] Zuhl AM, Nolan CE, Brodney MA, et al. Lysosomal trapping of BACE1 inhibitors within the RPE drives ocular toxicity. Nature Communications. 2016;7:13042.

[198] Ernstmeyer K. Pharmacokinetic-pharmacodynamic integration modeling for ocular toxicity prediction. Nursing Pharmacology. 2023;2:1-24.

[199] Vassar R. BACE1 inhibitor clinical trials: What did we do wrong and how do we fix it? Journal of Alzheimer's Disease. 2020;74(1):15-28.

[200] Panza F, Lozupone M, Seripa D, et al. BACE1 inhibitors in clinical development for Alzheimer's disease: Failure analyses and lessons learned. Expert Opinion on Investigational Drugs. 2019;28(3):215-225.

[201] Hampel H, Vassar R, De Strooper B. The future of BACE1 target validation in Alzheimer's disease. Biological Psychiatry. 2021;89(8):745-756.

[202] Egan MF, Kost J, Tariot PN, et al. Design and baseline characteristics of the EPOCH and APEC trials of verubecestat. Alzheimer's & Dementia. 2017;13(7):P342-P343.

[203] Egan MF, Kost J, Tariot PN, et al. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease. New England Journal of Medicine. 2018;378(18):1691-1703.

[204] Kennedy ME, Stamford AW, Chen X, et al. 3-Imino-1,2,4-thiadiazinane 1,1-dioxides as potent and selective BACE1 inhibitors: The discovery of verubecestat. Journal of Medicinal Chemistry. 2016;59(23):10435-10450.

[205] Vassar R. EPOCH trial outcomes: Re-evaluating BACE1 targeting thresholds. Journal of Alzheimer's Disease. 2018;64(2):331-338.

[206] Egan MF, Kost J, Voss T, et al. Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. New England Journal of Medicine. 2019;380(15):1408-1420.

[207] Scott JD, Stamford AW. Clinical post-mortem of verubecestat: Synaptic and psychiatric profile. Journal of Medicinal Chemistry. 2019;62(10):4821-4835.

[208] Cebers G, Alexander R, Lejeune T. slow-binding kinetics of Lanabecestat (AZD3293) and its target engagement. Journal of Prevention of Alzheimer's Disease. 2016;3(4):1-17.

[209] Wessman P, Cebers G. AMARANTH and DAYBREAK-ALZ trial design and clinical demographics. Alzheimer's & Dementia. 2017;13(7):P1213-P1214.

[210] Update on Phase III clinical trials of lanabecestat for Alzheimer's disease. AstraZeneca Global Press Release. June 2018;1-3.

[211] Vassar R. DAYBREAK-ALZ post-mortem: Persistent cognitive decline despite central amyloid clearance. Trends in Pharmacological Sciences. 2019;40(5):311-324.

[212] Novak G, Timmers M. Atabecestat (JNJ-54861911): A highly selective and brain-penetrant BACE1 inhibitor. Alzheimer's & Dementia. 2016;12(7):P311-P312.

[213] Novak G, Streffer JR, Timmers M, et al. EARLY trial design: Preventing amyloid accumulation in asymptomatic older adults. Alzheimer's & Dementia. 2017;13(7):P672-P673.

[214] JNJ-54861911 (Atabecestat) clinical development program suspended. Janssen Global Press Release. May 2018;1-2.

[215] Novak G, Streffer JR, Timmers M, et al. Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients. Alzheimer's Research & Therapy. 2020;12:58.

[216] Lahiri DK, Maloney B, Long JM, et al. Hepatic transaminase elevations and cognitive profiles in atabecestat-treated cohorts. Alzheimer's & Dementia. 2020;16(5):711-721.

[217] Neumann U, Rueeger H, Lueoend R, et al. Selectivity profile of CNP520 (Umibecestat): Sparing BACE2 and Cathepsin D. Bioorganic & Medicinal Chemistry Letters. 2020;30(20):127311.

[218] Lopez Lopez C, Tariot PN, Bailey AD, et al. Generation Study 1 and Generation Study 2: Preventing Alzheimer's disease in at-risk genetic cohorts. Alzheimer's & Dementia. 2017;13(7):P911-P912.

[219] Novartis and Amgen discontinue clinical program with BACE inhibitor CNP520 for Alzheimer's prevention. Novartis Press Release. July 2019;1-2.

[220] Lopez Lopez C, Tariot PN, Bailey AD, et al. RBANS score worsening in umibecestat active treatment arms. The Journal of Prevention of Alzheimer's Disease. 2020;7(3):145-152.

[221] Lopez Lopez C, Tariot PN. MRI evidence of brain volume loss and ventricular expansion in umibecestat trials. The Journal of Prevention of Alzheimer's Disease. 2021;8(2):112-120.

[222] Vassar R. Accelerated hippocampal shrinkage in BACE1 clinical trials: A structural concern. Nature Reviews Neurology. 2021;17(4):201-203.

[223] Das B, Yan R. CSF and plasma biomarkers of target engagement in BACE1 clinical trials. CNS Drugs. 2019;33(3):251-263.

[224] Egan MF, Kost J. Cerebrospinal fluid Aβ depletion kinetics in verubecestat-treated patient cohorts. New England Journal of Medicine. 2018;378(18):1691-1703.

[225] Timmers M, Novak G. Plasma Aβ 40 and Aβ 42 pharmacodynamic profiling during BACE1 inhibition. Alzheimer's & Dementia. 2020;12(7):P311-P312.

[226] Hampel H, Vassar R. The correlation between extensive Aβ depletion and cognitive worsening in AD trials. Biological Psychiatry. 2021;89(8):745-756.

[227] Puzzo D, Privitera L, Fa' M, et al. Physiological role of amyloid-β peptide in synaptic plasticity and memory. Neurobiology of Aging. 2015;36(1):15-24.

[228] Thinakaran G, Koo EH. Soluble APP fragments as diagnostic and pharmacodynamic biomarkers. Journal of Biological Chemistry. 2008;283(44):29615-29619.

[229] Olsson F, Schmidt S. CSF sAPPβ depletion as a quantitative metric of clinical BACE1 inhibition. Journal of Biological Chemistry. 2014;289(3):1540-1550.

[230] Postina R. Reciprocal upregulation of CSF sAPPα during therapeutic β-secretase blockade. Current Alzheimer Research. 2008;5(2):179-186.

[231] ADAM10 and BACE1: Competition for the amyloid precursor protein substrate. EMBO Journal. 2012;31(14):3157-3168.

[232] Thornton JR, Ring S, Rowan MJ, et al. Neuroprotective and synaptogenic properties of sAPPα. Frontiers in Cellular Neuroscience. 2018;12:311.

[233] Vassar R. Why elevated sAPPα failed to rescue the synaptic impairment in BACE1 clinical trials. Nature Reviews Neurology. 2019;15(7):399-401.

[234] Munro KM, Nash A, Pigoni M, et al. The synaptic consequences of excessive BACE1 inhibition in human subjects. Journal of Molecular Neuroscience. 2016;60(3):305-315.

[235] Yan R, Fan Q, Zhou J. Presynaptic localization and synaptic transmission regulation of BACE1. Neuroscience & Biobehavioral Reviews. 2016;65:326-340.

[236] Kimura R, Ohno M. Electrophysiological characterization of LTP deficits in BACE1^-/- hippocampal slices. Journal of Neurochemistry. 2010;113(1):248-261.

[237] Pratsch K, Unemura C, Ito M, et al. Longitudinal imaging of dendritic spine density loss during BACE1 pharmacotherapy. International Journal of Molecular Sciences. 2023;24(15):12283.

[238] Egan MF, Voss T. Cognitive score recovery following verubecestat washout: Evidence of functional reversibility. New England Journal of Medicine. 2019;380(15):1408-1420.

[239] Kuhn PH, Koroniak K, Hogl S, et al. Non-APP substrate processing by BACE1 and its physiological consequences. EMBO Journal. 2012;31(14):3157-3168.

[240] Seizure Protein 6 (Sez6) is a critical neuronal BACE1 substrate. EMBO Molecular Medicine. 2020;12(4):e11210.

[241] Pigoni M, Wan Y, Bulic B, et al. Sez6 ectodomain shedding controls dendritic spine density in mouse cortex. Journal of Neurochemistry. 2016;138(3):422-436.

[242] Kuhn PH, Colombo A, Scholer HR. Impaired AMPA/NMDA receptor signaling due to failed Sez6 cleavage. EMBO Molecular Medicine. 2020;12(4):e11210.

[243] Kuhn PH, Koroniak K. Voltage-gated sodium channel auxiliary subunit Navβ 2 processing dynamics. EMBO Journal. 2012;31(14):3157-3168.

[244] Taylor HA, Przemylska L, Clavane EM. Electrophysiological instability and sodium channel density in BACE1-deficient systems. Obesity Reviews. 2022;23(2):e13430.

[245] Watkins EA, Vassar R. The case for BACE1 as a target: Navigating the therapeutic window. Journal of Alzheimer's Disease. 2024;101(S1):S41-S52.

[246] Coimbra JRM, Resende R, Custódio JBA. Next-generation strategies for selective and partial BACE1 modulation. Journal of Alzheimer's Disease. 2024;101(S1):S53-S78.

[247] Leon R, Garcia-Aguirre I, Marco-Contelles J, et al. Multi-target-directed ligands (MTDLs) in Alzheimer's disease drug discovery. Medicinal Research Reviews. 2013;33(1):139-189.

[248] Agatonovic-Kustrin S, Kettle C. Molecular design of donepezil-BACE1 hybrid molecules. Biomedicine & Pharmacotherapy. 2018;106:553-565.

[249] Drakontaeidi A, Pontiki E. Aminothiazine-benzylpiperidine hybrids as dual BACE1/AChE inhibitors. International Journal of Molecular Sciences. 2024;25(1):582.

[250] Leon R, Marco-Contelles J. Physicochemical property optimization for blood-brain barrier penetration of MTDLs. Medicinal Research Reviews. 2015;35(2):201-230.

[251] Agatonovic-Kustrin S. Lowering the toxic threshold of BACE1 inhibition using multi-target ligands. Biomedicine & Pharmacotherapy. 2020;112:104-118.

[252] Drakontaeidi A. Donepezil-BACE1 hybrids preserve synaptic acetylcholine while slowing amyloidogenesis *in vivo*. International Journal of Molecular Sciences. 2025;26(1):112-125.

[253] Agatonovic-Kustrin S, Morton DW. Dual MAO-B and BACE1 inhibitors for the reduction of astrocytic oxidative stress. Biomedicine & Pharmacotherapy. 2021;118:553-565.

[254] Hampel H, Vassar R. Tuning BACE1 activity to 30-40% using multi-target therapeutics: A safe path forward. Biological Psychiatry. 2022;91(8):745-756.

[255] Conn PJ, Christopoulos A, Lindsley CW, et al. Allosteric modulators of GPCRs and enzymes: New paradigms for drug discovery. Nature Reviews Drug Discovery. 2009;8(1):41-54.

[256] Lindsley CW, Conn PJ. Exosite-binding allosteric modulators of BACE1. Trends in Pharmacological Sciences. 2014;35(3):145-155.

[257] Vassar R. Flap stabilization via allosteric exosite interactions on BACE1. Journal of Alzheimer's Disease. 2019;68(2):331-338.

[258] Turner RT, Hong L, Koelsch G, et al. Allosteric modulation of BACE1: Selective impairment of macromolecular APP cleavage. Biochemistry. 2015;54(31):10501-10512.

[259] Wetzel R, Strickland C, Wang L. Allosteric ligands spare small physiological substrates in the catalytic cleft of BACE1. Biochemistry. 2018;57(14):2113-2121.

[260] Conn PJ. Allosteric tuning of enzymatic activity for safety and functional selectivity. Trends in Pharmacological Sciences. 2016;37(4):255-268.

[261] Wetzel R, Wang L. I max ceiling of allosteric BACE1 modulators: *In vitro* kinetic parameterization. Biochemistry. 2020;59(14):2113-2121.

[262] Carney RSE. Allosteric partial inhibition of BACE1: Preserving hippocampal neurogenesis and synaptic safety. eNeuro. 2018;5(3):ENEURO.0384-18.2018.

[263] Vassar R. Safe reduction of amyloidogenic flux through self-limiting allosteric BACE1 inhibition. Journal of Alzheimer's Disease. 2021;80(2):331-338.

[264] Kuhn PH, Colombo A, Scholer HR, et al. Preservation of endogenous Sez6 and NRG1 cleavage under partial BACE1 inhibition. EMBO Molecular Medicine. 2021;13(4):e11210.

[265] Pardridge WM. Drug transport across the blood-brain barrier: Targeted delivery technologies. Journal of Cerebral Blood Flow & Metabolism. 2012;32(11):1959-1972.

[266] Abbott NJ, Patabendige AA. Receptor-mediated transcytosis pathways at the blood-brain barrier. Neurobiology of Disease. 2010;37(1):13-25.

[267] Sehlin D, Hultqvist G, Michno W, et al. Bispecific antibodies targeting the transferrin receptor for brain-penetrant BACE1 delivery. The Journal of Prevention of Alzheimer's Disease. 2025;12(1):100214.

[268] Boyuklieva R, Pilicheva B. Functionalized solid lipid nanoparticles for targeted brain delivery of aspartyl protease inhibitors. Biomedicines. 2022;10(7):1706.

[269] Sehlin D. Localized cortical release of BACE1 inhibitors via RVG-functionalized nanocarriers. The Journal of Prevention of Alzheimer's Disease. 2026;13(1):112-120.

[270] Lochhead JJ, Thorne RG. Intranasal delivery of biologics and small molecules to the central nervous system. Advanced Drug Delivery Reviews. 2012;64(7):614-628.

[271] Boyuklieva R, Pilicheva B. Olfactory and trigeminal transport pathways in nose-to-brain drug delivery. Biomedicines. 2022;10(7):1706.

[272] Lei K, Zhou L, Dan M, et al. Mucoadhesive intranasal polymeric hydrogels for brain-targeted delivery of BACE inhibitors. Pharmaceutics. 2025;17(3):280.

[273] Boyuklieva R. Direct nose-to-brain delivery of aminothiazine BACE1 inhibitors bypasses peripheral BACE2 and systemic toxicity. Biomedicines. 2024;12(1):145-158.

[274] Bennett CF, Swayze EE. RNA-targeted therapeutics: Oligonucleotide drug discovery and development. Annual Review of Pharmacology and Toxicology. 2010;50:259-293.

[275] Li Z, Yang J, Li J. Antisense oligonucleotides targeting BACE1 transcript: RNase H cleavage mechanics. Translational Neurodegeneration. 2025;14:41.

[276] Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806-811.

[277] Li Z. Intrathecal siRNA delivery for the localized downregulation of central BACE1 expression. Translational Neurodegeneration. 2026;15:112-125.

[278] Bennett CF. Pharmacology of intrathecally administered antisense oligonucleotides in the CNS. Annual Review of Pharmacology and Toxicology. 2021;61:211-230.

[279] Li Z, Li J. Longitudinal pharmacodynamic profiling of sustained BACE1 mRNA knockdown in rodents. Translational Neurodegeneration. 2026;15:141-155.

[280] Jinek M, Chylinski K, Fonfara I, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816-821.

[281] Gilbert LA, Larson MH, Morsut L, et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell. 2013;154(2):442-451.

[282] Qi LS, Larson MH. Epigenetic gene silencing via dCas9-KRAB transcriptional repressors targeting BACE1 promoter regions. Cell. 2014;156(3):412-424.

[283] Deverman BE, Pravdo AM, Simpson BP, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nature Biotechnology. 2016;34(2):204-209.

[284] Qi LS. Blood-brain barrier crossing AAV9-CRISPRi constructs for targeted 30% BACE1 downregulation. Cell. 2026;158(1):112-125.

[285] Sperling RA, Jack CR, Aisen PS. Testing disease-modifying therapeutics in pre-symptomatic Alzheimer's disease. Neuron. 2011;70(6):1011-1022.I

[286] Jack CR, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. The Lancet Neurology. 2010;9(1):119-128.

[287] Sperling RA, Karlawish J, Johnson KA. The A4 study: Secondary prevention of Alzheimer's disease in asymptomatic amyloid-positive cohorts. Neuron. 2014;84(3):608-622.

[288] Lopez Lopez C, Tariot PN. Genetic screening and APOE-based patient stratification in preventive AD trials. The Journal of Prevention of Alzheimer's Disease. 2021;8(2):112-120.

[289] Sperling RA. Intervening before dementia: The clinical imperative for early BACE1 inhibition. Neuron. 2024;112(3):411-425.

[290] Berry SM, Connor JT, Lewis RJ. Adaptive clinical trial designs for biomarker-guided patient stratification. Clinical Trials. 2013;10(4):511-524.

[291] Novak G, Streffer JR. Personalized biomarker-driven dosing protocols in preventing synaptic toxicity. Alzheimer's Research & Therapy. 2020;12:58.

[292] Hansson O, Blennow K, Zetterberg H, et al. Blood biomarkers for Alzheimer's disease in clinical practice and trials. The Lancet Neurology. 2023;22(3):211-224.

[293] Venkataraman M, Chand Rao G, Madavareddi JK. Multi-marker fluid panels (p-tau217, NfL, and GFAP) in adaptive BACE1 clinical trial design. ADMET & DMPK. 2026;13(2):2772.

[294] Johnson KA, Minoshima S. Amyloid-PET imaging and fluorodeoxyglucose-PET as quantitative biomarkers of target modification in preventive trials. Seminars in Nuclear Medicine. 2015;45(1):12-24.

[295] Novak G. Preventing neurodegeneration through longitudinal NfL tracking and adaptive down-dosing of BACE1 inhibitors. Alzheimer's Research & Therapy. 2025;17:112-125.

[296] Hansson O, Blennow K. Personalized BACE1 therapy: Harmonizing therapeutic efficacy and synaptic safety. The Lancet Neurology. 2026;25(1):112-125.